

Supporting Information

Efficient Amidation of Weak Amines: Synthesis, Chiral Separation by SFC, and Antimicrobial Activity of *N*-(9, 10-dioxo-9, 10-dihydroanthracene-1-yl) carboxamide

Kathiravan Asokan,¹ A. Zahir Hussain² and Andivelu Ilangovan,^{3*}

¹Aragen Life Sciences Pvt. Ltd. Bengaluru-562106, India.

²Department of Chemistry, Jamal Mohamed College, Tiruchirappalli, Tamilnadu-620020, India.

³School of Chemistry, Bharathidasan University, Tiruchirappalli, Tamilnadu-620024, India.

Email: ilangovanbdu@yahoo.com

Table of Contents


1	General Information	S2
2	General procedure for the synthesis of compounds 2a and 2b	S2
3	Experimental procedure and characterization of synthesized compounds	S3
4	SFC Experimental Procedure	S19
5	General Procedure for Antibacterial Activity	S21
6	Copies of ¹ H NMR, ¹³ C NMR Spectra	S23-S77
7	Copies of HRMS data	S78-100
8	SFC chromatogram	S101- S109
9	Optical Rotation values for compounds 4a , 4a' 4b and 4b'	S110 – S113

1. General Information:

All the reagents were purchased commercially and used without further purification. ^1H NMR and ^{13}C NMR were recorded with Bruker 400 MHz. ^1H NMR (400MHz) and ^{13}C NMR (100MHz) spectra were recorded in CDCl_3 with tetramethylsilane as the internal standard. Multiplicities are reported using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, sep = septet, br = broad resonance. All the NMR spectra were acquired at ambient temperature. Analytical thin layer chromatography (TLC) was performed using Silica Gel 60 Å F₂₅₄ pre-coated plates (0.25 mm thickness). Visualization was accomplished by irradiation with a UV lamp and staining with I₂ on silica gel. High resolution mass spectra (HRMS) were recorded on Bruker Compass Data Analysis 4.1, HRMS-ESI Mass Spectrometer with Orbitrap Exploris-240 Analyzer, Source Type ESI, in positive mode.

2. Experimental Procedure

2.1. General procedure for the synthesis of (*tert*-butoxycarbonyl)proline (**2a**) and 1-(*tert*-butoxycarbonyl)piperidine-2-carboxylic acid (**2b**)



To a suspension of DL-proline (1.0 equiv.) in THF: H₂O (1:1), sodium bicarbonate (3.0 equiv.) was added and stirred at room temperature for 30 min, then boc anhydride (1.05 equiv.) was added and stirred for 12 h. The reaction mixture was monitored by TLC. The reaction mixture was concentrated under reduced pressure. The residue was adjusted pH-2 by using aqueous citric acid solution. The aqueous layer was extracted with ethyl acetate (3 x 20 mL), washed with water, brine solution and combined organic layer was dried anhydrous sodium sulphate, filtered and concentrated under reduced pressure to get the desired product **2a** or **2b**.

1-(*tert*-butoxycarbonyl)proline (DL-2a): ^1H NMR (400 MHz, DMSO-*d*₆) δ 1.34-1.39 (d, J = 20.80 Hz, 9H), 1.80-1.86 (m, 3H), 2.14-2.18 (m, 1H), 3.26-3.30 (m, 2H), 4.03-4.08 (m, 1H), 12.40 (br, 1H). ELSD purity: 99.91% LCMS: 214.08 [M+H]⁺


1-(*tert*-butoxycarbonyl)piperidine-2-carboxylic acid (DL-2b): ^1H NMR (400 MHz, DMSO-*d*₆) δ 1.05-1.15 (m, 1H), 1.23-1.39 (m, 10H), 1.59-1.62 (m, 3H), 2.06 (m, 1H), 2.74-2.96 (m, 1H), 3.78 (m, 1H), 4.53-4.61 (d, J = 29.20 Hz, 1H), 12.71 (s, 1H). ELSD purity: 99.95% LCMS: 228.14 [M+H]⁺

2.2. General procedure for synthesis of (±) 3a and (±) 3b

To a suspension of DL-pyrrolidine-1, 2-dicarboxylic acid 1-*tert*-butyl ester 2a (0.3 mmol) and DIPEA (0.5 mmol) in THF, COMU (0.25 mmol) was added at 0 °C. After 30 min 1-aminoanthraquinone 1 (0.25 mmol) was added. The resulting reaction mixture was stirred at 0 °C for 1 h and refluxed for 24 h. After completion of reaction (by TLC), reaction mixture was cooled to rt and diluted with water then extracted with ethyl acetate (3 x 20 mL). The combined organic layer was washed with water, brine solution, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. Crude product was purified through super critical fluid chromatography (Chiralcel-OX3, Methanol) to obtain the pair of enantiomers of (±)-3a.


3. Experimental procedure and characterization of synthesized compounds

tert-Butyl 2-((9,10-dioxo-9,10-dihydroanthracen-1-yl)carbamoyl)pyrrolidine-1-carboxylate (±)-3a



The reaction was carried out according to the general procedure A using 1a (56 mg, 0.25 mmol), 2a (64 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0-55 °C, 24 h. Yield: (70 mg, 66%). ¹HNMR (400 MHz, DMSO-*d*₆) δ 1.23-1.45 (d, *J* = 87.9 Hz, 9H), 1.90-2.06 (m, 3H), 2.25-2.38 (m, 1H), 3.48-3.55 (m, 1H), 3.64-3.73 (m, 1H), 4.27-4.31 (m, 1H), 7.92-7.98 (m, 4H), 8.17-8.24 (m, 2H), 9.01-9.07 (m, 1H), 12.46-12.61 (d, *J* = 60.0 Hz, 1H).

tert-butyl 2-((9,10-dioxo-9,10-dihydroanthracen-1-yl)carbamoyl)piperidine-1-carboxylate (±)-3b



The reaction was carried out according to the general procedure A using 1 (56 mg, 0.25 mmol), 2b (69 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0-55 °C, 24 h. Yield: (69 mg, 63%). ¹HNMR (400 MHz, DMSO-*d*₆) δ 1.23-1.64

(m, 15H), 2.97 (br, 1H), 4.05 (m, 1H), 4.92 (m, 1H), 7.91-7.99 (m, 4H), 8.18-8.19 (m, 2H), 9.07-9.09 (m, 1H), 12.60 (s,1H).

2.4 NMR studies

The ^1H and ^{13}C NMR values for compound (-)-**4a** and (+)-**4a'**, assigned on the basis of 2D NMR spectral data (HSQC and HMBC), and are given in Table 1.




Figure 1. (a) General numbering and HMBC correlations for proline derivative

Table 1. ^1H NMR and ^{13}C NMR spectral data for proline derivative, assignments based on HSQC and HMBC correlations

S.No.	Assignment	Type of atom	^1H Chemical shift (ppm)	^{13}C Chemical shift (ppm)
1	1	C	-	118.19
2	2	C	-	185.31
3	3	C	-	133.80
4	4	C	-	132.10
5	5	C	-	182.30
6	6	C	-	133.73
7	7	CH	8.23 (m)	126.94
8	8	CH	7.93 (m)	134.62
9	9	CH	7.93 (m)	134.31
10	10	CH	8.16 (m)	126.28
11	11	CH	7.92 (m)	121.60
12	12	CH	7.86 (t)	135.26
13	13	CH	9.12 (dd)	125.21

14	14	C	-	140.65
15	15	O	-	-
16	16	O	-	-
17	17	NH	13.18 (s)	-
18	18	C	-	176.27
19	19	CH	3.85 (m)	61.45
20	20	CH ₂	2.15, 1.86 (m)	30.79
21	21	CH ₂	1.69 (m)	25.96
22	22	CH ₂	3.13, 2.96 (m)	46.87
23	23	NH	-	-
24	24	O	-	-

NOTE: m: multiplet, t: triplet d: doublet, s: singlet, dd: doublet of doublet, br: broad

b. Pipecolic acid analogue




Figure 2. General numbering and HMBC correlations of pipecolic acid derivative

Table 2. ¹HNMR and ¹³CNMR spectral data (chemical shifts) for pipecolic acid derivative

S.No.	Assignment	Type of atom	¹ H Chemical shift (ppm)	¹³ C Chemical shift (ppm)
1	1	C	-	118.09
2	2	C	-	185.68
3	3	C	-	133.89
4	4	C	-	132.23
5	5	CO	-	182.37
6	6	C	-	133.75
7	7	CH	8.23 (m)	127.10
8	8	CH	7.93 (m)	134.74
9	9	CH	7.93 (m)	134.50
10	10	CH	8.16 (m)	126.39
11	11	CH	7.92 (m)	121.69
12	12	CH	7.86 (t)	135.47
13	13	CH	9.12 (dd)	125.50
14	14	C	-	141.04
15	15	O	-	-
16	16	O	-	-
17	17	NH	12.78 (s)	-
18	18	C	-	174.31
19	19	CH	3.36 (m)	66.42
20	20	CH ₂	1.87, 1.56 (m)	29.00
21	21	CH ₂	1.72, 1.46 (m)	23.57
22	22	CH ₂	2.99, 2.69 (m)	44.92
23	23	NH	-	-
24	24	O	-	-

25

25


CH₂

1.52, 1.44 (m)

25.51

Note: Assignments made on the basis of HSQC and HMBC correlations, m: multiplet, t: triplet
d: doublet, s: singlet, dd: doublet of doublet, br: broad.


***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide (3c)**



N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide

The reaction was carried out according to the general procedure A using **1a** (56 mg, 0.25 mmol), 2-((1*s*,4*s*)-4-methylcyclohexyl)acetic acid (**2c**) (47 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0-55 °C, 24 h. Yield: (59 mg, 65%), the product **3c** was obtained as a *cis* and *trans* isomers and it was successfully separated by using SFC.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-((1*s*,4*s*)-4-methylcyclohexyl)acetamide (3c')**




¹H NMR (400 MHz, DMSO-*d*₆) δ 12.10 (s, 1H), 8.99 (q, *J* = 3.2 Hz, 1H), 8.25 (m, *J* = 2.2 Hz, 1H), 8.18 (m, *J* = 2.2 Hz, 1H), 7.92 (m, *J* = 4.0 Hz, 4H), 2.50 (d, *J* = 1.4 Hz, 1H), 2.09 (q, *J* = 4.0 Hz, 1H), 1.53 (m, *J* = 6.8 Hz, 7H), 1.31 (m, *J* = 4.5 Hz, 2H), 0.94 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 24.8, 28.0, 55.3, 59.1, 60.9, 117.6, 121.7, 125.4, 126.4, 127.0, 132.3, 133.7, 133.8, 134.7, 134.7, 135.7, 141.4, 162.7, 172.2, 182.2, 186.6. HRMS (ESI), Calcd. for C₂₃H₂₄O₃N (M+H)⁺: 362.1751; found: 362.1741.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide- Isomer-1 (3c')**

As Isomer-2 assigned as *trans* form, isomer-1 will be *cis* form. However H21 and H24 protons splitting pattern was not clear. Hence it is difficult to fix the relative stereo chemistry.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-((1*r*,4*r*)-4-methylcyclohexyl)acetamide (3c'')**




¹HNMR (400 MHz, DMSO-*d*₆) δ 12.10 (s, 1H), 9.00 (q, *J* = 3.2 Hz, 1H), 8.26 (q, *J* = 3.0 Hz, 1H), 8.19 (m, *J* = 2.2 Hz, 1H), 7.94 (m, *J* = 3.4 Hz, 4H), 2.40 (d, *J* = 6.7 Hz, 1H), 2.08 (d, *J* = 7.5 Hz, 1H), 1.78 (m, *J* = 10.5 Hz, 3H), 1.68 (d, *J* = 12.4 Hz, 2H), 1.31 (m, *J* = 4.8 Hz, H), 1.08 (m, *J* = 6.4 Hz, 2H), 0.96 (m, *J* = 12.1 Hz, 2H), 0.87 (m, *J* = 6.5 Hz, 4H). ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 24.8, 28.0, 55.3, 59.1, 60.9, 117.6, 121.7, 125.4, 126.4, 127.0, 132.3, 133.7, 133.8, 134.7, 134.7, 135.7, 141.4, 162.7, 172.2, 182.2, 186.6.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide-Isomer-2 (3c''')**


In HSQC, we could see CH21(1.92 ppm) at 35.00ppm and CH24(1.33 ppm) at 32.00 ppm. In COSY, H19(2.42 ppm)is coupling with H21 and H27(0.89 ppm) is coupling with H24. In ¹HNMR (Homo nuclear decoupling), we could see H21 (*J* value 11.60Hz) and H24 (*J* value 10.00Hz). Based on above *J* values H21 (Axial) and H24 (Axial) protons are in *trans* form.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide (3d)**




The reaction was carried out according to the general procedure A using **1a** (57 mg, 0.25 mmol), biotin (**2d**) (73 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0-55 °C, 24 h. Yield: (80 mg, 71%), ¹HNMR (400 MHz, DMSO-*d*₆) δ 12.11 (s, 1H), 9.00 (d, *J* = 8.0 Hz, 1H), 8.23 (m, *J* = 7.4 Hz, 2H), 7.94 (q, *J* = 8.5 Hz, 4H), 6.41 (d, *J* = 42.3 Hz, 2H), 4.25 (m, *J* = 16.2 Hz, 2H), 3.15 (d, *J* = 4.6 Hz, 1H), 2.83 (q, *J* = 5.8 Hz, 1H), 2.58 (t, *J* = 9.0 Hz, 4H), 1.72 (q, *J* = 7.3 Hz, 3H), 1.50 (m, *J* = 11.9 Hz, 4H). ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 24.8, 28.0, 55.3, 59.1, 60.9, 117.6, 121.7, 125.4, 126.4, 127.0, 132.3, 133.7, 133.8, 134.7, 134.7, 135.7, 141.4, 162.7, 172.2, 182.2, 186.6. HRMS (ESI), Calcd. for C₂₄H₂₄N₃O₄S (M+H)⁺ : 450.1482 ; found: 450.1478.

2-(4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide (**3e**)




The reaction was carried out according to the general procedure A using **1a** (60 mg, 0.25 mmol), 2-(4,4-difluorocyclohexyl)acetic acid (**2e**) (53 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0-55 °C, 24 h. Yield: (56 mg, 58%), ¹HNMR (400 MHz, DMSO-*d*₆) δ 12.08 (s, 1H), 8.99 (q, *J* = 3.2 Hz, 1H), 8.26 (m, *J* = 2.2 Hz, 1H), 8.19 (m, *J* = 2.2 Hz, 1H), 7.93 (m, *J* = 3.1 Hz, 4H), 2.53 (s, 2H), 2.05 (q, *J* = 9.5 Hz, 4H), 1.85 (m, *J* = 6.0 Hz, 4H), 1.34 (q, *J* = 11.6 Hz, 1H). ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 24.8, 28.0, 55.3, 59.1, 60.9, 117.6, 121.7, 125.4, 126.4, 127.0, 132.3, 133.7, 133.8, 134.7, 134.7, 135.7, 141.4, 162.7, 172.2, 182.2, 186.6. HRMS (ESI), Calcd. for C₂₂H₂₀O₃NF₂ (M+H)⁺ : 384.1399 ; found: 384.1399.

2-(4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide (**3f**)




The reaction was carried out according to the general procedure A using **1a** (56 mg, 0.25 mmol), 4-hydroxybutanoic acid (**2f**) (31 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0-55 °C, 24 h. Yield: (49 mg, 63%), ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.11 (s, 1H), 9.00 (d, *J* = 8.0 Hz, 1H), 8.23 (m, *J* = 7.4 Hz, 2H), 7.94 (q, *J* = 8.5 Hz, 4H), 6.41 (d, *J* = 42.3 Hz, 2H), 4.25 (m, *J* = 16.2 Hz, 2H), 3.15 (d, *J* = 4.6 Hz, 1H), 2.83 (q, *J* = 5.8 Hz, 1H), 2.58 (t, *J* = 9.0 Hz, 4H), 1.72 (q, *J* = 7.3 Hz, 3H), 1.50 (m, *J* = 11.9 Hz, 4H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 24.8, 28.0, 55.3, 59.1, 60.9, 117.6, 121.7, 125.4, 126.4, 127.0, 132.3, 133.7, 133.8, 134.7, 134.7, 135.7, 141.4, 162.7, 172.2, 182.2, 186.6. HRMS (ESI), Calcd. for C₁₈H₁₄O₄N(M-H)⁺ : 308.0922 ; found: 309.0918

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3-methylbenzamide (**3h**)



The reaction was carried out according to the general procedure A using **1a** (60 mg, 0.25 mmol), 3-methylbenzoic acid (**2h**) (41 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield : (64 mg, 75%). ¹H NMR (400 MHz, CDCl₃) δ 13.25 (s, 1H), 9.36 (q, *J* = 3.3 Hz, 1H), 8.37 (m, *J* = 1.8 Hz, 1H), 8.30 (m, *J* = 1.5 Hz, 1H), 8.11 (q, *J* = 2.9 Hz, 1H), 7.97 (t, *J* = 3.6 Hz, 2H), 7.83 (m, *J* = 2.5 Hz, 3H), 7.48 (m, *J* = 4.0 Hz, 1H), 7.43 (t, *J* = 3.9 Hz, 1H), 2.51 (s, 3H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 21.7, 118.2, 122.8, 124.8, 126.5, 127.3, 127.7, 128.7, 129.0, 133.0, 133.3, 134.3, 134.5, 134.6, 134.8, 136.1, 139.0, 142.7, 167.0, 182.4, 187.8. HRMS (ESI), Calcd. for C₂₂H₁₅NO₃ (M+H)⁺: 342.1125 ; found: 342.1121.


N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-methoxybenzamide (**3i**)



The reaction was carried out according to the general procedure A using **1a** (55 mg, 0.25 mmol), 4-methoxybenzoic acid (**2i**) (46 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol),


COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield : (55 mg, 61%). ¹HNMR (400 MHz, CDCl₃) δ 13.25 (s, 1H), 9.37 (q, *J* = 3.2 Hz, 1H), 8.37 (m, *J* = 2.3 Hz, 1H), 8.31 (m, *J* = 2.3 Hz, 1H), 8.16 (d, *J* = 8.9 Hz, 2H), 8.10 (q, *J* = 2.9 Hz, 1H), 7.83 (m, *J* = 3.2 Hz, 3H), 7.08 (d, *J* = 8.8 Hz, 2H), 3.92 (s, 3H); ¹³CNMR (DMSO-*d*₆, 100 MHz) δ 55.7, 114.4, 118.0, 122.7, 126.4, 127.0, 127.3, 127.7, 129.9, 133.1, 134.3, 134.3, 134.5, 134.6, 136.1, 143.0, 163.2, 166.3, 183.0, 187.9. HRMS (ESI), Calcd. for C₂₂H₁₆NO₄(M+H)⁺ : 358.1074 ; found: 358.1069.

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-(trifluoromethoxy)benzamide (3j)



The reaction was carried out according to the general procedure A using **1a** (57 mg, 0.25 mmol), 4-(trifluoromethoxy)benzoic acid (**2j**) (62 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield : (57 mg, 55%). ¹HNMR (400 MHz, CDCl₃) δ 13.36 (s, 1H), 9.34 (q, *J* = 3.2 Hz, 1H), 8.36 (m, *J* = 2.3 Hz, 1H), 8.31 (m, *J* = 2.3 Hz, 1H), 8.23 (q, *J* = 2.9 Hz, 2H), 8.13 (q, *J* = 2.9 Hz, 1H), 7.85 (m, *J* = 2.4 Hz, 3H), 7.43 (d, *J* = 8.2 Hz, 2H); ¹³C NMR (DMSO-*d*₆, 100 MHz) δ 118.2, 121.1, 123.1, 126.4, 127.4, 127.7, 129.8, 133.1, 133.1, 134.2, 134.3, 134.6, 134.8, 136.3, 142.5, 152.4, 165.4, 182.8, 188.0. HRMS (ESI), Calcd. for C₂₂H₁₃NF₃(M+H)⁺ : 412.0791 ; found: 412.0788.


N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-nitro benzamide (3k)



The reaction was carried out according to the general procedure A using 1-aminoanthracene-9,10-dione (**1a**) (56 mg, 0.25 mmol), 2-nitrobenzoic acid (**2l**) (47.5 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield: 48% ; ¹HNMR (400 MHz, DMSO-*d*₆) δ 12.59 (s, 1H), 8.97 (q, *J* = 3.1 Hz, 1H), 8.21 (q, *J* = 3.2 Hz, 3H), 8.08 (q, *J* = 3.0 Hz, 1H), 8.02 (q, *J* = 5.3 Hz, 3H), 7.96 (m, *J* = 4.4 Hz, 2H),


7.88 (m, $J = 3.4$ Hz, 1H), Ion trap LCMS(ESI), Calcd. for $C_{21}H_{12}N_2O_5(M+H)^+$: 373.07 ; found: 373.03.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3,5-dimethylbenzamide (3l)**




The reaction was carried out according to the general procedure A using **1a** (56 mg, 0.25 mmol), 3,5-dimethylbenzoic acid (**2l**) (45 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield : (62 mg, 70%). 1H NMR (400 MHz, DMSO-*d*6) δ 13.21 (s, 1H), 9.36 (d, $J = 7.8$ Hz, 1H), 8.39 (m, $J = 2.2$ Hz, 1H), 8.31 (m, $J = 2.2$ Hz, 1H), 8.11 (q, $J = 2.8$ Hz, 1H), 7.84 (m, $J = 3.4$ Hz, 3H), 7.76 (s, 2H), 4.09 (d, $J = 6.4$ Hz, 1H), 3.64 (s, 5H), 2.47 (s, 6H). ^{13}C NMR (DMSO-*d*6, 100 MHz) δ 21.6, 118.2, 122.8, 125.7, 126.6, 127.3, 127.7, 133.1, 134.2, 134.3, 134.5, 134.6, 134.8, 136.1, 138.8, 142.8, 167.3, 183.0, 187.7. HRMS (ESI), Calcd. for $C_{23}H_{18}NO_3(M+H)^+$: 356.1281 ; found: 356.1276.

3-cyano-*N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-fluorobenzamide (3m)




The reaction was carried out according to the general procedure A using 1-aminoanthracene-9,10-dione (**1a**) (60 mg, 0.25 mmol), 3-cyano-4-fluorobenzoic acid (**2m**) (50 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield : (49 mg, 52%), 1H NMR (400 MHz, DMSO-*d*6) δ 12.92 (s, 1H), 9.03 (d, $J = 7.5$ Hz, 1H), 8.53 (m, $J = 4.1$ Hz, 1H), 8.42 (m, $J = 2.3$ Hz, 1H), 8.28 (q, $J = 3.0$ Hz, 1H), 8.20 (q, $J = 3.0$ Hz, 1H), 8.00 (m, $J = 4.6$ Hz, 4H), 7.86 (t, $J = 9.0$ Hz, 1H); ^{13}C NMR (DMSO-*d*6, 100 MHz) δ 101.2, 101.4, 113.4, 117.6, 117.8, 118.7, 122.6, 125.8, 126.5, 127.2, 131.8, 132.2, 133.5, 133.5, 134.7, 134.8, 134.9, 135.9, 140.7, 162.9, 163.2, 165.8, 182.0, 186.8. HRMS (ESI), Calcd. for $C_{22}H_{12}FN_2O_3(M+H)^+$: 371.0826 ; found: 371.0822.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3,5-difluorobenzamide (3n)**




The reaction was carried out according to the general procedure A using **1** (56 mg, 0.25 mmol), 3,5-difluorobenzoic acid (**2n**) (47.5 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield: trace ; ¹HNMR (400 MHz, DMSO-*d*₆) δ 13.38 (s, 1H), 9.33 (q, *J* = 3.2 Hz, 1H), 8.40 (m, *J* = 2.3 Hz, 1H), 8.34 (m, *J* = 2.2 Hz, 1H), 8.17 (q, *J* = 2.9 Hz, 1H), 8.03 (m, *J* = 3.7 Hz, 2H), 7.88 (m, *J* = 3.1 Hz, 3H), 7.41 (q, *J* = 8.6 Hz, 1H). HRMS (ESI), Calcd. for C₂₁H₁₂NF₂O₃(M+H)⁺: 364.0780 ; found: 364.0775.

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-1 naphthamide (3p)**



The reaction was carried out according to the general procedure A using **1** (56 mg, 0.25 mmol), 1-naphthoic acid (**2p**) (47.5 mg, 0.3 mmol), DIPEA (87 mg, 0.5 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 - 55 °C, 24 h. Yield: 58 % ; ¹HNMR (400 MHz, DMSO-*d*₆) δ 12.78 (s, 1H), 9.25 (q, *J* = 3.2 Hz, 1H), 8.43 (m, *J* = 1.6 Hz, 1H), 8.21 (m, *J* = 2.5 Hz, 3H), 8.05 (m, *J* = 3.8 Hz, 4H), 7.93 (m, *J* = 2.7 Hz, 2H), 7.74 (q, *J* = 5.1 Hz, 1H), 7.66 (m, *J* = 1.9 Hz, 2H). Ion trap LCMS(ESI), Calcd. for C₂₁H₁₂NF₂O₃(M+H)⁺: 378.10 ; found: 377.82.


***N,N'*-(9,10-dioxo-9,10-dihydroanthracene-1,5-diyl)bis(pyrrolidine-2-carboxamide) (5)**



The reaction was carried out according to the general procedure A using 1,5-diaminoanthracene-9,10-dione (**1b**) (200 mg, 0.084 mmol), (tert-butoxycarbonyl)proline (**2a**) (398 mg, 1.85 mmol), DIPEA (542 mg, 4.2 mmol), COMU (540 mg, 1.26 mmol). Conditions: 0- 55 °C, 24 h. Yield : 58 % ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.98 (s, 2H), 9.54 (br, 4H), 8.70 (q, *J*=3.0Hz, 2H), 7.98 (m, *J*=7.1Hz,4H), 4.67(t, *J* = 7.8 Hz 2H), 3.29 (q, *J*=5.6Hz, 4H), 2.55 (m, *J* = 5.3 Hz, 2H), 2.18 (m, *J*=7.0Hz,2H),2.03 (m, *J*=6.7Hz, 4H); ¹³CNMR(DMSO-*d*₆,100MHz) δ185.14,167.99,139.09,135.84,134.49,126.88,


123.24118.99, 60.43, 45.45, 29.10, 23.58; HRMS (ESI): Calcd. for C₁₉H₁₆N₂O₃ (M+H)⁺, 433.180; found. 433.1868.

tert-butyl 2-((2-acetylphenyl)carbamoyl)pyrrolidine-1-carboxylate (**5a**)




The reaction was carried out according to the general procedure A using 1-(2-aminophenyl)ethan-1-one (**1c**) (200 mg, 1.48 mmol), (tert-butoxycarbonyl)proline (**2a**) (382 mg, 1.78 mmol), DIPEA (573 mg, 4.44 mmol), COMU (951mg, 2.22 mmol). Conditions: 0- 55 °C, 24 h. Yield : 61% ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.47 (d, *J*=71.2 1H), 7.83 (q, *J*=23.5, 1H), 7.64 (m, *J*=6.5Hz, 4H), 7.48 (m, *J*=8.3Hz,3H), 7.28(t, *J* = 7.2 Hz 1H), 4.11 (m, *J*=6.4Hz, 1H), 3.32 (m, *J* = 14.44 Hz, 2H), 1.91 (t, *J*=9.7 Hz,1H),1.62(d, *J*=6.8Hz, 2H), 1.30 (d, *J*=32.1Hz, 10H).; ¹³C NMR (DMSO-*d*₆, 100MHz) δ 195.97, 195.56, 171.16, 170.89, 153.70, 153.04, 137.34, 136.73, 132.53, 132.21, 131.19, 130.75, 129.41, 129.25, 128.23, 127.94, 123.95, 123.63, 122.73, 122.18, 78.86, 78.58, 60.40, 46.58, 46.36, 29.97, 29.16, 27.95, 27.86, 23.78, 23.07.; HRMS (ESI): Calcd. for C₁₈H₂₄N₂O₄ (M+H)⁺, 334.40; found. 334.9854

tert-butyl 2-((2-(methoxycarbonyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (**5b**)




The reaction was carried out according to the general procedure A using methyl 2-aminobenzoate (**1d**) (200 mg, 1.32 mmol), (tert-butoxycarbonyl)proline (**2a**) (342 mg, 1.59 mmol), DIPEA (513 mg, 3.97 mmol) COMU (850 mg, 1.95 mmol). Conditions: 0-55 °C - rt, 24 h. Yield : 48%; ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.09 (d, J=7.7 Hz, 1H), 7.63 (q, J=5.2Hz,1H), 7.19 (t, J=7.5Hz, 1H), 4.20 (s,1H), 3.87 (s, 3H), 3.45 (m, J=9.6Hz,2H), 2.26 (s,1H), 1.92 (m, J=12.8Hz, 3H), 1.34 (d, J+69.5Hz, 9H).; ¹³CNMR (DMSO-*d*₆,100MHz) 171.69, 171.47, 167.54, 154.04, 153.13, 139.73, 134.32, 130.70, 123.07, 120.10, 119.82, 116.49, 115.88, 79.23, 78.96, 61.84, 61.60, 52.47, 46.80, 46.55, 30.86, 29.97, 28.03, 27.76, 23.90, 23.30; HRMS (ESI): Calcd. for C₁₈H₂₄N₂O₅ (M+H)⁺, 349.3999; found. 349.1728.

tert-butyl 2-((3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate (5e**)**




The reaction was carried out according to the general procedure A using methyl 3-amino-2-methylbenzoate (**1f**) (200 mg, 1.21 mmol), (tert-butoxycarbonyl)proline (**2a**) (313 mg, 1.45 mmol), DIPEA (469mg, 3.63 mmol), COMU (778 mg, 1.82 mmol). Conditions: 0-55 °C - rt, 24 h. Yield : 45% ; ¹H NMR (400 MHz, CDCl₃) δ 9.12 (s, 1H), 8.05(s, 1H), 7.60(s, 1H), 7.23 (t, J=7.9Hz,1H), 4.51(s, 1H), 3.88 (s, 3H), 3.45 (s, 2H), 2.60 (s, 1H), 2.45(s,3H); 1.95 (s, 3H), 1.49 (s, 9H). ; ¹³CNMR (CDCl₃-101MHz) 170.30, 168.40, 156.51, 137.20, 131.40, 130.21, 126.39, 125.85, 80.99, 60.53, 52.05, 47.29, 28.41, 27.30, 24.65, 14.61; HRMS (ESI): Calcd. for C₁₉H₂₆N₂O₅ (M+H)⁺, 363.426; found. 363.1965.

tert-butyl 2-((5-bromo-3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate (5e)



The reaction was carried out according to the general procedure A using methyl 3-amino-5-bromo-2-methylbenzoate (**1g**) (200 mg, 0.82 mmol), (tert-butoxycarbonyl)proline (**2a**) (212 mg, 0.98 mmol), DIPEA (318 mg, 2.46 mmol), COMU (526 mg, 1.23 mmol). Conditions: 0 -55°C - rt, 24 h. Yield: 46%; ¹H NMR (400 MHz, CDCl₃) δ 9.12 (s, 1H), 8.05 (s, 1H), 7.60 (s, 1H), 7.23 (t, 4H), 4.67(t, *J* = 7.9 Hz, 1H), 4.51 (s, 1H), 3.88 (s, 3H), 3.45 (s, 9H). ¹³CNMR (CDCl₃, 101MHz): δ 170.28, 167.07, 156.62, 138.56, 132.55, 128.69, 128.10, 119.02, 81.09, 60.50, 52.30, 47.30, 28.40, 27.10, 24.64, 14.32. HRMS (ESI): Calcd. for C₁₉H₂₅BrN₂O₅ (M-H)⁻, 440.3220; found. 439.087 & 440.087.

tert-butyl 2-((6-methoxypyridazin-3-yl)carbamoyl)pyrrolidine-1-carboxylate (5f)




The reaction was carried out according to the general procedure A using 6-methoxypyridazin-3-amine (**1h**) (200 mg, 1.60 mmol), (tert-butoxycarbonyl)proline (**2a**) (413 mg, 1.92 mmol), DIPEA (620 mg, 4.79 mmol), COMU (1.03 g, 2.40 mmol). Conditions: 0-55 °C - rt, 24 h. Yield : 53% ; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (d, *J*=20.8Hz,1H), 8.23 (t, *J*=9.5Hz, 1H), 7.26 (t, *J*=9.9Hz, 1H), 4.40 (m, *J*=6.1Hz 1H), 3.98 (s, *J* = 7.8 Hz 2H), 7.94-8.01 (m, 4H), 8.70 (dd, *J* = 7.9 Hz, 1.20 Hz 2H), 9.54 (br, 4H), 11.98 (s, 3H) 3.39(q, *J*=5.6Hz,2H), 2.21 (q, *J*=6.9Hz,1H), 1.84 (m, *J*=7.0 Hz,3H) 1.33 (d, *J*=51.7Hz,9H).; HRMS (ESI): Calcd. for C₁₅H₂₂N₄O₄ (M+H)⁺, 323.365; found. 323.170.

2.5. General procedure (B) for synthesis of (+)-4a', (-)-4a, (+)-4b' & (-)-4b.


To a stirred solution of compound (+)-**3a'**, (-)-**3a**, (+)-**3b'** & (-)-**3** (1.0 equiv.) in THF (5 mL) at 0 °C was added 5M HCl (5 mL) and continued the stirring for 25 h at room temperature. After completion, the reaction mixture was concentrated under vacuum to obtain the residue, which was neutralized with aq. NaHCO₃ and extracted with DCM. The organic layer was dried over Na₂SO₄ and concentrated under vacuum to obtain (+)-**4a'**, (-)-**4a**, (+)-**4b'** & (-)-**4b**.

(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide



The reaction was carried out according to the general procedure B using (+)-**3a'** (105 mg, 0.25 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 °C - rt, 25 h. Yield : 40% ; MP : 156-158 °C; $[\alpha]_D^{25} +36.20$ (c = 0.1, Acetonitrile) ; ¹HNMR (400 MHz, DMSO-*d*₆) δ 1.65-1.72 (m, 2H), 1.83-1.91 (m, 1H), 2.07-2.17 (m, 1H), 2.94-2.98 (m, 1H), 3.07-3.13 (m, 1H), 3.84-3.88 (dd, *J* = 9.2 Hz, 5.3 Hz, 1H), 7.86 (t, *J* = 7.8 Hz, 1H), 7.90-7.95 (m, 3H), 8.15-8.17 (m, 1H), 8.22-8.24 (m, 1H), 9.12 (dd, *J* = 8.3 Hz, 1.2 Hz, 1H) 13.18 (s, 1H); ¹³CNMR (DMSO-*d*₆, 100 MHz): δ 25.9, 30.8, 46.8, 61.4, 118.2, 121.6, 125.2, 126.3, 126.9, 132.1, 133.7, 133.8, 134.3, 134.6, 135.2, 140.6, 176.2, 182.3, 185.3; Chiral purity (ee) by SFC: 98.40%; FT-IR (film cm⁻¹) 3362, 2964, 1661, 1497, 1264, 804. HRMS (ESI): Calcd. for C₁₉H₁₆N₂O₃ (M+H)⁺, 321.1234; found. 321.1228.


(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide



The reaction was carried out according to the general procedure B using (-)-**3a** (105 mg, 0.25 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 °C - rt, 25 h. Yield 38%; MP: 162-164 °C. $[\alpha]_D^{25} -41.72$ (c = 0.1, Acetonitrile) ; ¹HNMR (400 MHz, DMSO-*d*₆) δ 1.65-1.72 (m, 2H), 1.83-1.91 (m, 1H), 2.07-2.17 (m, 1H), 2.94-2.98 (m, 1H), 3.07-3.13 (m, 1H), 3.84-3.88 (dd, *J* = 9.2 Hz, 5.3 Hz, 1H), 7.86 (t, *J* = 7.8 Hz, 1H), 7.90-7.95 (m, 3H), 8.15-8.17 (m, 1H), 8.22-8.24 (m, 1H), 9.12 (dd, *J* = 8.3 Hz, 1.2 Hz, 1H) 13.18 (s, 1H); ¹³CNMR (DMSO-*d*₆, 100


MHz) δ 25.9, 30.8, 46.8, 61.4, 118.2, 121.6, 125.2, 126.3, 126.9, 132.1, 133.7, 133.8, 134.3, 134.6, 135.2, 140.6, 176.2, 182.3, 185.3; Chiral purity(ee) by SFC: 98.72 %, FT-IR (film) cm^{-1} 3362, 2964, 1661, 1497, 1264, 804 ; HRMS (ESI): Calcd. for $\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}_3$ ($\text{M}+\text{H}$) $^+$, 321.1234; found. 321.1224.

(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide (+)4b'



The reaction was carried out according to the general procedure B using (-)-**3b'** (109 mg, 0.25 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 °C - rt, 25 h. Yield : 35% ; MP; 160-162 °C; $[\alpha]_{\text{D}}^{25} = +26.78$ (c = 0.1, Acetonitrile) ; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 1.43-1.57 (m, 4H), 1.71-1.73 (m, 1H), 1.86-1.89 (m, 1H), 2.67-2.70 (m, 1H), 2.99-3.02 (m, 1H), 3.36 (m, 1H), 7.87-7.97 (m, $J = 7.8$ Hz, 4H), 8.17-8.19 (m, 1H), 8.25-8.27 (m, 1H), 9.12 (dd, $J = 8.3$ Hz, 1.2 Hz, 1H) 12.78 (br, 1H); ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz) δ 23.5, 25.5, 29.0, 49.9, 60.4, 118.0, 121.6, 125.5, 126.3, 127.1, 132.2, 133.7, 133.8, 134.5, 134.7, 135.4, 141.0, 174.3, 182.3, 185.6; Chiral purity(ee) by SFC: 99.98%, FT-IR (film cm^{-1}) 3302, 2927, 1697, 1508, 1264, 705; HRMS (ESI), Calcd. for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_3$ ($\text{M}+\text{H}$) $^+$: 335.1390 ; found: 335.1352.

(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide



The reaction was carried out according to the general procedure B using (-)-**3b** (109 mg, 0.25 mmol), COMU (107 mg, 0.25 mmol). Conditions: 0 °C - rt, 25 h. Yield : 37%; MP 158-160 °C; $[\alpha]_{\text{D}}^{25} = -27.06$ (c = 0.1, Acetonitrile); ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 1.43-1.57 (m, 4H), 1.71-1.73 (m, 1H), 1.86-1.89 (m, 1H), 2.67-2.70 (m, 1H), 2.99-3.02 (m, 1H), 3.36 (m, 1H), 7.87-7.97 (m, $J = 7.8$ Hz, 4H), 8.17-8.19 (m, 1H), 8.25-8.27 (m, 1H), 9.12 (dd, $J = 8.3$ Hz, 1.2 Hz, 1H) 12.78 (br, 1H); ^{13}C NMR ($\text{DMSO}-d_6$, 100 MHz) δ 23.5, 25.5, 29.0, 49.9, 60.4, 118.0, 121.6, 125.5, 126.3, 127.1, 132.2, 133.7, 133.8, 134.5, 134.7, 135.4, 141.0, 174.3, 182.3, 185.6 Chiral purity (ee) by SFC: 99.86% FT-IR (film cm^{-1}) 3302, 2929, 1696, 1508, 1266, 707. HRMS (ESI), Calcd. for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_3$ ($\text{M}+\text{H}$) $^+$: 335.1390 ; found: 335.1353.

NMR abbreviations: s-singlet, d-doublet, t-triplet, m-multiplet, q-quartet, br-broad, dd-doublet of doublet.

4. SFC Experimental Procedure

Materials

Reagents

Methanol (MeOH), acetonitrile (ACN), Trifluoroacetic acid (TFA), diethylamine (DEA) and 7N Methanolic ammonia, Isopropanol (IPA), were of HPLC grade and purchased from Sigma-Aldrich Co. (Merck-INDIA).

Compounds

L- or D-pyrrolidine-2-carboxylic acid (9,10-dioxo-9,10-dihydro-anthracen-1-yl)-amide (I-II), L& D piperidine-2-carboxylic acid (9,10-dioxo-9, 10-dihydro-anthracen-1-yl)-amide (III-IV) were synthesized internally. The purity of the compounds was at least 95%. Structures of four derivatives are listed in Fig. 1.

Columns

Four analytical coated and immobilized polysaccharide-based chiral SFC columns (Chiralpak- IA (4.6X150) mm,3 μ , Chiralpak-IB(4.6X150) mm,3 μ , Chiralpak-IC (4.6X150) mm,3 μ , Chiralpak-ID (4.6X150)mm,3 μ , Chiralpak-IE (4.6X150)mm,3 μ , Chiralpak-IF and Chiralpak-IG (4.6X150) mm,3 μ and Chiralcel-OX-3 (4.6X150) mm,3 μ SFC columns were purchased from Chiral Technologies (West Chester, PA, USA). Lux-cellulose-2 and Lux-amylose -2 (4.6 X 250)mm,5 μ were purchased from Phenomenex (Torrance, CA, USA). One Whelk-O 1 (RR) (4.6 X 250) mm,5 μ was purchased from Regis (Morton Grove, IL, USA).

SFC instrumentation

Analytical Acquity UPC2 PDA (Waters) with a six-position modifier and column-switching valves, Thar SFC method development stations (SFC Method Station) with a six-position modifier and a ten-position column switching valves, and Waters SFC150Mgm prep were all purchased from Waters (WATERS GES MBH, W-Austria).

Methods

Analytical SFC methods

All analytical SFC experiments were performed either on Acquity UPC2 PDA or a Waters analytical SFC system. All method development work was performed on (4.6X150) mm, 3 μ dimension columns under gradient or isocratic conditions at a back-pressure of 100 bar, a temperature of 30 °C, a flow rate of 3 ml/min, and a wavelength of 215 nm. The initial gradient program was run from 10% to 50% Co-solvents for 8 min, and 50% co-solvent for an additional 4 min. 30% of the Co-solvent ratio was stabilized for scale-up.

Preparative SFC methods

All preparative SFC separations were carried out on Chiralcel-OX-H (30X250)mm,5 μ column on Waters 150Mgm SFC instrument under isocratic conditions at a back pressure of 100 bar and a temperature of 30 °C.

Sample solution

Preparation For all the analytical SFC experiments, compounds (\pm)-**3a**, (\pm)-**3b** and **3d** were dissolved in MeOH at a concentration of \sim 1 mg/ml. For the preparative-scale SFC, 1-1.25 g of crude (\pm)-**3a**, (\pm)-**3b** and **3d** were dissolved in MeOH at 100 mg/ml. Total purification was completed within 2 hours of time with 50 mg/injection.

5.0 General Procedure for Antibacterial activity

The bacterial and fungal pathogens obtained from Microbial Type Culture Collection (MTCC), Chandigarh, and Government of India. The synthesized compounds were tested for their antibacterial efficacy against both gram positive and gram negative bacterial pathogens. The Gram-positive bacterial pathogens were *Vibrio cholera* (MTCC 3906), *Salmonella typhi* (MTCC 531) and *Pseudomonas aeruginosa* (MTCC 1688). The Gram negative bacterial pathogens were *Rhodococcus rhodochrous* (MTCC-265), *Mycobacterium smegmatis* (MTCC-994) and *Micrococcus luteus* (MTCC 1809). The synthesized compounds were tested for their antifungal efficacies against the fungal pathogens were *Pichia jadinii* MTCC 185, *Candida parapsilosis* MTCC 7043 and *Candida glabrata* MTCC 3019.

Determination of MIC and MBC values of synthesised compounds

The minimum inhibitory concentration (MIC) was determined to espouse the serial dilution technique using 96-well microplates. All the bacterial strains were prepared by Muller Hinton agar, and the turbidity of all the bacterial strains was adjusted to 0.5 McFarland Standard by making a bacterial suspension of three to five well-isolated colonies of the same morphological type selected from an agar plate culture. The cultures were further, diluted 1,000-fold to get an inoculum size of 1.5×10^5 CFU/mL. 100 μ L of sterilized Mueller Hinton broth added into the wells of a 96-well plate. The first row served as growth control. Then, the highest concentration (64 μ g) of 100 μ L of compounds (+)-4a', (-)-4a, (+)-4b' & (-)-4b, samples were poured in the second row of the plate. The compound dissolved in dimethyl sulfoxide (DMSO) serially diluted to create a concentration sequence from 64 to 1 mg/ml was tested against bacterial pathogens. The first row served as growth control. Finally, 10 μ L of bacterial suspensions were added to deep wells of the plate incubated for 24 h at 37 °C. The streptomycin sulphate is used as a positive control. The resulting turbidity observed, and after 24 h, MIC determined as one where growth was no longer visible by assessment of turbidity by optical density reading at 600 nm in a microplate reader. The MBC values are the least concentration of an antibacterial compound that prevents the growth of the organism on the agar plates. It is evaluated by subculturing broth dilutions that of MIC values determined microplate. The dilutions are streaked onto sterilized Mueller Hinton agar plates and incubated for 24 hours. No growth on the plate implies that no viable organisms found in broth.

Determination of MIC and MFC values


The determination of MIC and MFC for the synthesized compounds (+)-**4b'** & (-)-**4b** was assessed by the broth micro dilution method. 100 μ L of YPD broth added into the wells of a 96-well plate. The first row served as growth control. Then, the highest concentration (64 μ g) of 100 μ L of compounds (+)-**4a'**, (-)-**4a**, (+)-**4b'** & (-)-**4b** samples were poured in the second row of the plate. Doubled serial dilutions, where a 100 μ L aliquot removed from the most concentrated well went to the next well, and yielded concentrations of 64 to 1 μ g/mL. Finally, 10 μ L of yeast inoculum suspensions were added to each well of the plate and incubated at 37 °C for 24 h. After incubation the inhibition of visible growth defined as the MIC. This MIC value was further confirmed by Resazurin dye assay. The MFC defined as the minimal concentration of tested compounds required to kill 99.9% the yeast. The dilutions are streaked onto YPD agar plates and incubated for 24 h. No growth on the Petri dishes implies that no viable organisms found in the broth.

Resazurin dye assay

The 750 mg of Resazurin dye was dissolved in 100 ml sterile water. Vortex mixer used to homogenize the solution. This solution then referred to as Resazurin dye solution. After incubated followed by the serial dilution technique using 96-well microplates, 10 μ l of Resazurin solution as the indicator added in each well. The plates were again incubated in a temperature-controlled incubator at 37 °C for 4 h. The colour change in the well then observed visually. The purple to pink colour changes taken indicates the growth inhibition of microbes. The lowest concentration of compound at which colour change occurred recorded as the MIC value.


6. Copies of ¹H NMR, ¹³C NMR Spectra

(*tert*-butoxycarbonyl)proline (2a) -¹H NMR spectra



1-(*tert*-butoxycarbonyl)piperidine-2-carboxylic acid (DL-2b)- ¹HNMR spectra

N-BOC-2 PIPERIDINE



```


Current Data Parameters
NAME      N-BOC-2 PIPERIDINE
EXPNO     1
PROCNO    1

F2 - Acquisition Parameters
Date_     20210301
Time      14.01 h
INSTRUM   spect
PROBHD    Z116098_0794 (
PULPROG   zg30
TD         32768
SOLVENT   DMSO
NS         64
DS         2
SWH        8012.820 Hz
FIDRES     0.489064 Hz
AQ         2.0447233 sec
RG         54.97
DW         62.400 usec
DE         6.50 usec
TE         298.1 K
D1         1.00000000 sec
TD0        1
SFO1       400.2324714 MHz
NUC1       1H
P0         3.33 usec
P1         10.00 usec
PLW1       17.25300026 W

F2 - Processing parameters
SI         65536
SF         400.2300021 MHz
WDW        EM
SSB        0
LB         0.30 Hz
GB         0
PC         1.00
    
```

tert-Butyl 2-((9,10-dioxo-9,10-dihydroanthracen-1-yl)carbamoyl)pyrrolidine-1-carboxylate (\pm)-3a-1H NMR spectra

Proline-BOC-Protected



```


Current Data Parameters
NAME      Proline-BOC-Protected
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20210215
Time     17.40 h
INSTRUM  spect
PROBHD   zg30
PULPROG  zg30
ID       32768
SOLVENT  DMSO
NS       32
DS       2
SWH      8012.820 Hz
FIDRES   0.489064 Hz
AQ       2.0447233 sec
RG       204.36
DW       62.400 usec
DE       6.50 usec
TE       298.1 K
D1       1.00000000 sec
ID0      1
SFO1     400.2324714 MHz
NUC1     1H
FO       3.33 usec
F1       10.00 usec
PLW1     17.25300026 W

F2 - Processing parameters
SI       65536
SF       400.2300014 MHz
WDW      EM
SSB      0
LB       0.30 Hz
GB       0
PC       1.00
    
```

tert-butyl 2-((9,10-dioxo-9,10-dihydroanthracen-1-yl)carbamoyl)piperidine-1-carboxylate (\pm)**3b**- ¹H NMR spectra

pipecolic acid boc-protected



```


Current Data Parameters
NAME      Pipecolic acid Boc protected
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20210220
Time     19.56 h
INSTRUM  AV4 400NB ANL-BLR-NMR-03
PROBHD   Z163739_0196 (
PULPROG  zg30
ID       32786
SOLVENT  DMSO
NS       8
DS       2
SWH      8196.722 Hz
FIDRES   0.500013 Hz
AQ       1.9999460 sec
RG       101
DW       61.000 usec
DE       13.89 usec
TE       298.2 K
D1       1.0000000 sec
TD       1
SFO1     400.1324708 MHz
NUC1     1H
PD       2.67 usec
P1       8.00 usec
P1M1     24.26700020 W

F2 - Processing parameters
SI       65536
SF       400.1300026 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.00
    
```

(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide -1HNMR spectra

D-PROLINE-CPD FREE BASE



Current Data Parameters
 NAME D-PROLINE-CPD FREE BASE
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190729
 Time 20.07 h
 INSTRUM Avance Neo Nanobay
 PROBHD Z163739_0079 {
 PULPROG zg30
 TD 32786
 SOLVENT DMSO
 NS 8
 DS 2
 SWH 8196.722 Hz
 FIDRES 0.500013 Hz
 AQ 1.9999460 sec
 RG 101
 DW 61.000 usec
 DE 13.54 usec
 TE 298.1 K
 D1 1.00000000 sec
 TDO 1
 SFO1 400.5324733 MHz
 NUC1 1H
 PO 3.33 usec
 P1 10.00 usec
 PLW1 15.46500015 W

F2 - Processing parameters
 SI 65536
 SF 400.5300002 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



NMR-02

(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide -13C spectra

D-PROLINE-CPD FREE BASE

185.398
182.394
176.328
140.686
135.316
134.678
134.359
133.877
133.799
132.172
126.990
126.334
125.262
121.650
118.282

61.461
46.885
40.122
39.913
39.705
39.496
39.288
39.079
38.871
30.811
25.969



Current Data Parameters
NAME D-PROLINE-CPD FREE BASE
EXPNO 4
PROCNO 1


F2 - Acquisition Parameters
Date_ 20190730
Time 8.07 h
INSTRUM Avance Neo Nanobay
PROBHD Z163739_0079 (4
PULPROG zgpg30
TD 65536
SOLVENT DMSO
NS 4000
DS 4
SWH 23809.523 Hz
FIDRES 0.726609 Hz
AQ 1.3762560 sec
RG 101
DW 21.000 usec
DE 6.50 usec
TE 298.2 K
D1 3.00000000 sec
D11 0.03000000 sec
TD0 1
SFO1 100.7234199 MHz
NUC1 13C
PO 3.33 usec
P1 10.00 usec
PLW1 56.74499893 W
SFO2 400.5316021 MHz
NUC2 1H
CPDPRG[2] waltz65
PCPD2 90.00 usec
PLW2 15.46500015 W
PLW12 0.18945029 W
PLW13 0.09495249 W

F2 - Processing parameters
SI 32768
SF 100.7133978 MHz
WDW EM
SSB 0
LB 2.00 Hz
GB 0
PC 1.40

NMR-02

(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide -2D NMR data

D-PROLINE-CPD FREE BASE



```

Current Data Parameters
NAME      D-PROLINE-CPD FREE BASE
EXPNO    3
PROCNO   1

F2 - Acquisition Parameters
Date_    20190730
Time     3.09 h
INSTRUM  Avance Neo NanoBey
PROBHD   1H3131_0079 (
PULPROG  zgpg30p0p0p0
TD       2048
SOLVENT  DMSO
NS       32
DS       16
SWH      6250.000 Hz
FIDRES   6.103516 Hz
AQ       0.1638400 sec
RG       101
DM       80.000 usec
DE       6.50 usec
TE       298.2 K
CNET2    145.0000000
CNET13   10.0000000
DO       0.0000000 sec
D1       1.5000000 sec
D2       0.0034828 sec
D4       0.0000000 sec
D16      0.0002000 sec
INDO     0.0002254 sec
TD0av    1
SFO1     400.5328003 MHz
NUC1     1H
P1       10.00 usec
P2       20.00 usec
P1M1     15.46500015 W
SFO2     100.7234199 MHz
NUC2     13C
P3       10.00 usec
P1M2     56.74499893 W
CPDAM[1] 2MSQ10.100
CPD1     50.00 %
CPDAM[2] 2MSQ10.100
CPD2     20.00 %
CPDAM[3] 2MSQ10.100
CPD3     40.10 %
P16      1000.00 usec


F1 - Acquisition parameters
TD       388
SFO1     100.7234 MHz
FIDRES   114.230232 Hz
SN       220.015 ppm
F1M00K   QF

F2 - Processing parameters
SI       2048
SF       400.5300002 MHz
WDW      SINE
SSB      0
LB       0 Hz
GB       0
PC       1.40

F1 - Processing parameters
SI       1024
MC2      QF
SF       100.7133486 MHz
WDW      SINE
SSB      0
LB       0 Hz
GB       0

```

(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide -1HNMR spectra




Current Data Parameters
 NAME L-PROLINE COUPLED
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20190725
 Time 14.58 h
 INSTRUM Avance Neo Nanobay
 PROBHD Z163739_0079 ()
 PULPROG zg30
 TD 32786
 SOLVENT DMSO
 NS 16
 DS 2
 SWH 8196.722 Hz
 FIDRES 0.500013 Hz
 AQ 1.9999460 sec
 RG 101
 DW 61.000 usec
 DE 13.54 usec
 TE 298.1 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.5324733 MHz
 NUC1 1H
 P0 3.33 usec
 P1 10.00 usec
 PLW1 15.46500015 W

F2 - Processing parameters
 SI 65536
 SF 400.5300004 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

NMR-02

(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide -13C spectra



```


Current Data Parameters
NAME      L-PROLINE COUPLED
EXPNO     5
PROCNO    1

F2 - Acquisition Parameters
Date_     20190728
Time      7.02 h
INSTRUM   Avance Neo Nanobay
PROBHD    Z163739_0079 (
PULPROG   zgpg30
TD         65536
SOLVENT   DMSO
NS         7000
DS         4
SWH        23809.523 Hz
FIDRES     0.726609 Hz
AQ         1.3762560 sec
RG         101
DW         21.000 usec
DE         6.50 usec
TE         298.2 K
D1         3.00000000 sec
D11        0.03000000 sec
TD0        1
SFO1       100.7234199 MHz
NUC1       13C
P0         3.33 usec
P1         10.00 usec
PLW1       56.74499893 W
SFO2       400.5316021 MHz
NUC2       1H
CPDPRG[2]  waltz65
PCPD2      90.00 usec
PLW2       15.46500015 W
PLW12      0.18945029 W
PLW13      0.09495249 W

F2 - Processing parameters
SI         32768
SF         100.7133985 MHz
WDW        EM
SSB        0
LB         2.00 Hz
GB         0
PC         1.40
    
```

NMR-02

(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide -2D NMR data



```


Current Data Parameters
NAME      L-PROLINE COUPLED
EXPNO     4
PROCNO    1

F2 - Acquisition Parameters
Date_     20190727
Time      22.23 h
INSTRUM   Avance Neo Machray
PROBHD    Z163739_0079 (
PULPROG   hmcgcp1pndqr
TD         2048
SOLVENT    DMSO
NS         32
DS         16
SWH        5882.353 Hz
FIDRES     5.744485 Hz
AQ         0.1740800 sec
RG         101
DE         85.000 usec
TE         298.1 K
CNST12    145.0000000
CNST13    10.0000000
D0         0.00000300 sec
D1         1.50000000 sec
D2         0.00344828 sec
D5         0.05000000 sec
D16        0.00020000 sec
IN0        0.00002256 sec
T1ay      1
SFO1      400.528749 MHz
NUC1       1H
P1         10.00 usec
P2         20.00 usec
P3         15.46500015 n
SFO2      100.7234199 MHz
NUC2       13C
P3         10.00 usec
PLW2      56.74499893 W
CP1AM[1]  SMSQ10.100
CP21      50.00 %
CP1AM[2]  SMSQ10.100
CP22      30.00 %
CP1AM[3]  SMSQ10.100
CP23      40.10 %
P16        1000.00 usec

F1 - Acquisition parameters
TD         600
SFO1      100.7234 MHz
FIDRES     73.868881 Hz
SW         220.015 ppm
FMODE     QF


F2 - Processing parameters
SI         2048
SF         400.5299961 MHz
WIM        SINE
SSB         0
LB          0 Hz
GB          0
PC          1.40

F1 - Processing parameters
SI         1024
MC2        QF
SF         100.7133486 MHz
WIM        SINE
SSB         0
LB          0 Hz
GB          0
    
```



(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide- 1HNMR spectra

PIPECOLIC ACID DERIVATIVE PK-2



```

Current Data Parameters
NAME      PIPECOLIC ACID DERIVATIVE PK-2
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20190906
Time     18.43 h
INSTRUM  Avance Neo Nanobay
PROBHD   Z163739_0079 (
PULPROG  zg30
ID       65536
SOLVENT  DMSO
NS       16
DS       2
SWH      8196.722 Hz
FIDRES   0.250144 Hz
AQ       3.9976959 sec
RG       101
IW       61.000 usec
DE       13.54 usec
TE       298.2 K
D1       1.0000000 sec
ID0      1
SFO1     400.5324733 MHz
NUC1     1H
PO       3.33 usec
P1       10.00 usec
PLW1     15.46500015 W



F2 - Processing parameters
SI       65536
SF       400.5300018 MHz
WDW      EM
SSB      0
LB       0.30 Hz
GB       0
PC       1.00
    
```

(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide- 13C spectra

PIPECOLIC ACID DERIVATIVE PK-2

185.68
182.38
174.31
141.04
135.47
134.74
134.50
133.89
133.75
132.23
127.11
126.40
125.50
121.70
116.10

60.43
44.93
40.12
39.91
39.70
39.49
39.29
39.08
38.87
39.01
38.52
33.57





Current Data Parameters
NAME PIPECOLIC ACID DERIVATIVE PK-2
EXPNO 14
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190908
Time 0.48 h
INSTRUM Avance Neo Manobay
PROBHD Z163739_0079 (zppg30
PULPROG zgpg30
TD 65536
SOLVENT DMSO
NS 4000
DS 4
SWH 23809.523 Hz
FIDRES 0.726609 Hz
AQ 1.3762560 sec
RG 101
DW 21.000 usec
DE 6.50 usec
TE 298.1 K
D1 3.00000000 sec
D11 0.03000000 sec
TDO 1
SFO1 100.7234199 MHz
NUC1 13C
P0 3.33 usec
P1 10.00 usec
PLW1 56.74499893 W
SFO2 400.5316021 MHz
NUC2 1H
CPDPRG12 waltz65
PCPD2 90.00 usec
PLW2 15.46500015 W
PLW12 0.18945029 W
PLW13 0.09495249 W

F2 - Processing parameters
SI 32768
SF 100.7133981 MHz
WDW EM
SSB 0
LB 2.00 Hz
GB 0
PC 1.40


(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide- 2D spectra

PIPECOLIC ACID DERIVATIVE PK-2



(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide- 1HNMR spectra

PIPECOLIC ACID DERIVATIVE PK-1



```

Current Data Parameters
NAME      PIPECOLIC ACID DERIVATIVE PK-1
EXPNO    5
PROCNO   1

F2 - Acquisition Parameters
Date_    20190907
Time     15:35 h
INSTRUM  spect
PROBHD   Z116098_0794 (
PULPROG  zg30
TD       65536
SOLVENT  DMSO
NS       8
DS       2
SWH      8012.820 Hz
FIDRES   0.244532 Hz
AQ       4.0894465 sec
RG       149.06
IW       62.400 usec
DE       6.50 usec
TE       298.1 K
D1       1.00000000 sec
TD0      1
SFO1    400.2324714 MHz
NUC1     1H
P1       9.80 usec
PLW1    17.89999962 W



F2 - Processing parameters
SI       65536
SF       400.2300111 MHz
WDW      EM
SSB      0
LB       0.50 Hz
GB       0
PC       1.00
    
```

(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide- 13C spectra

PIPECOLIC ACID DERIVATIVE PK-1

185.64
182.33
174.34
141.05
135.44
134.72
134.47
133.95
133.72
132.20
127.09
126.37
125.47
121.66
116.04

60.44
44.94
40.12
39.91
39.70
39.50
39.29
39.08
38.87
38.66
38.45
38.24
38.03
37.82
37.61





```

Current Data Parameters
NAME      PIPECOLIC ACID DERIVATIVE PK-1
EXPNO     9
PROCNO    1

F2 - Acquisition Parameters
Date_     20190908
Time      5.31 h
INSTRUM   spect
PROBHD    Z116098_0794 (
PULPROG   zgpg30
TD         65536
SOLVENT   DMSO
NS         5000
DS         4
SWH        24038.461 Hz
FIDRES     0.733596 Hz
AQ         1.3631488 sec
RG         204.36
DW         20.800 usec
DE         6.50 usec
TE         298.1 K
D1         2.0000000 sec
D11        0.03000000 sec
TDO        1
SFO1       100.6479713 MHz
NUC1       13C
P1          9.80 usec
PLW1       86.30000305 W
SFO2       400.2316009 MHz
NUC2       1H
CPDPRG12  waltz16
PCPD2      90.00 usec
PLW2       17.89999962 W
PLW12      0.21224000 W
PLW13      0.10659000 W

F2 - Processing parameters
SI         32768
SF         100.6379632 MHz
WDW        EM
SSB        0
LB         2.00 Hz
GB         0
PC         1.40
    
```


(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide- 2D spectra



N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-5-((3*a*S,4*S*,6*a*R)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide (3d)

¹H NMR spectra

AK-B10



```

Current Data Parameters
NAME          AK-B10
EXPNO         1
PROCNO        1


F2 - Acquisition Parameters
Date_         20230116
Time          17.52 h
INSTRUM       AV4 400NB ANL-BLR-NMR-03
PROBHD        Z163739_0196 (
PULPROG       zg30
TD            32786
SOLVENT       DMSO
NS            8
DS            2
SWH           8196.722 Hz
FIDRES        0.500013 Hz
AQ            1.9999460 sec
RG            101
DW            61.000 usec
DE            13.89 usec
TE            298.2 K
D1            1.00000000 sec
TDO           1
SFO1          400.1324708 MHz
NUC1          1H
P0            2.67 usec
P1            8.00 usec
PLW1          24.26700020 W

F2 - Processing parameters
SI            65536
SF            400.1300026 MHz
WDW           EM
SSB           0
LB            0.80 Hz
GB            0
PC            1.00
    
```


N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-5-((3*a*S,4*S*,6*a*R)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide (3*d*)


¹³C spectra

AK-B10-13C




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-((1s,4s)-4-methylcyclohexyl)acetamide (3c')-1H NMR spectra

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide-Isomer-1




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-((1s,4s)-4-methylcyclohexyl)acetamide (3c')-13C spectra

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide-Isomer-1-13C




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-((1r,4r)-4-methylcyclohexyl)acetamide-1H NMR spectra

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide-Isomer-2




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-((1r,4r)-4-methylcyclohexyl)acetamide-13C spectra

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-(4-methylcyclohexyl)acetamide-Isomer-2-13C





(4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide (3e)-1HNMR spectra

2-(4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl) acetamide




4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide (3e)-19F




4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide (3e)-13C spectra

2-(4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide-13C



N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-hydroxybutanamide(3f)-1H NMR spectra

HBA



```


Current Data Parameters
NAME          HBA
EXPNO         1
PROCNO        1

F2 - Acquisition Parameters
Date_         20230308
Time          17.23 h
INSTRUM      AV4 400NB ANL-BLR-NMR-03
PROBHD       Z163739_0195 (
PULPROG      zg30
TD           32786
SOLVENT      DMSO
NS           64
DS           2
SWH          8196.722 Hz
FIDRES       0.500013 Hz
AQ           1.9999460 sec
RG           101
DW           61.000 usec
DE           13.89 usec
TE           298.2 K
D1           1.00000000 sec
TD0          1
SFO1         400.1324708 MHz
NUC1         1H
P0           2.67 usec
P1           8.00 usec
PLW1         24.03499985 W

F2 - Processing parameters
SI           65536
SF           400.1300024 MHz
WDW          EM
SSB          0
LB           0.30 Hz
GB           0
PC           1.00
    
```

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-hydroxybutanamide(3f)-13C spectra

HBA-13C




```

Current Data Parameters
NAME          HBA-13C
EXPNO         1
PROCNO        1

F2 - Acquisition Parameters
Date_         20230309
Time          11.48 h
INSTRUM       spect
PROBHD        Z116098_0561 (
PULPROG       zgpg30
TD            65536
SOLVENT       DMSO
NS            1800
DS            4
SWH           24038.461 Hz
FIDRES        0.733596 Hz
AQ            1.3631488 sec
RG            204.36
DW            20.800 usec
DE            6.50 usec
TE            298.1 K
D1            2.0000000 sec
D11           0.0300000 sec
TD0           1
SFO1          100.6479773 MHz
NUC1          13C
P0            3.33 usec
P1            10.00 usec
PLW1          71.33300018 W
SFO2          400.2316009 MHz
NUC2          1H
CPDPRG[2]    waltz65
PCPD2         90.00 usec
PLW2          16.51199913 W
PLW12         0.20385000 W
PLW13         0.10253000 W

F2 - Processing parameters
SI            32768
SF            100.6379634 MHz
WDW           EM
SSB           0
LB            2.00 Hz
GB            0
PC            1.40
    
```

N-(9, 10-dioxo-9,10-dihydroanthracen-1-yl)-3-methylbenzamide (3h)- 1H NMR spectra




Current Data Parameters
 NAME AC-28
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20230202
 Time 5.29 h
 INSTRUM AVNeo400-446284-Aragen
 PROBHD Z163739_0428 (
 PULPROG zg30
 ID 32768
 SOLVENT CDCl3
 NS 8
 DS 2
 SWH 8196.722 Hz
 FIDRES 0.500288 Hz
 AQ 1.9988480 sec
 RG 101
 DW 61.000 usec
 DE 13.89 usec
 TE 298.2 K
 D1 1.00000000 sec
 ID0 1
 SFO1 400.1424709 MHz
 NUC1 1H
 P0 2.67 usec
 P1 8.00 usec
 PLW1 24.83499908 W

F2 - Processing parameters
 SI 65536
 SF 400.1400093 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

N-(9, 10-dioxo-9,10-dihydroanthracen-1-yl)-3-methylbenzamide (3h)- ¹³C spectra

AC-28




```

Current Data Parameters
NAME          AC-28
EXPNO         2
PROCNO        1

F2 - Acquisition Parameters
Date_         20230202
Time          7.59 h
INSIRUM       AVNeo400-446284-Aragen
PROBHD        Z163739_0428 (
PULPROG       zgpg30
TD            65536
SOLVENT       CDC13
NS            2602
DS            4
SWH           23809.523 Hz
FIDRES        0.726609 Hz
AQ            1.3762560 sec
RG            101
DW            21.000 usec
DE            6.50 usec
TE            298.4 K
D1            2.00000000 sec
D11           0.03000000 sec
TD0           1
SFO1          100.6253446 MHz
NUC1          13C
P0            2.67 usec
P1            8.00 usec
PIW1          97.26999664 W
SFO2          400.1416006 MHz
NUC2          1H
CPDPRG[2]    waltz65
PCPD2         90.00 usec
PIW2          24.83499908 W
PIW12         0.19622999 W
PIW13         0.09870100 W


F2 - Processing parameters
SI            32768
SF            100.6152620 MHz
WDW           EM
SSB           0
LB            2.00 Hz
GB            0
PC            1.40
    
```

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-methoxybenzamide (**3i**)-1H NMR spectra



***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-methoxybenzamide (3i)- ¹³C spectra**

PMAQ-13C




Current Data Parameters
 NAME PMAQ
 EXPNO 12
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20230115
 Time 4.38 h
 INSTRUM Avance Neo Nanobay
 PROBHD Z163739_0079 ()
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 12000
 DS 4
 SWH 23809.523 Hz
 FIDRES 0.726609 Hz
 AQ 1.3762560 sec
 RG 101
 DW 21.000 usec
 DE 6.50 usec
 TE 298.2 K
 D1 2.00000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.7234199 MHz
 NUC1 ¹³C
 P0 3.33 usec
 P1 10.00 usec
 PLW1 59.21300125 W
 SFO2 400.5316021 MHz
 NUC2 ¹H
 CPDPRG[2] waltz65
 PCPD2 90.00 usec
 PLW2 15.97799969 W
 PLW12 0.19618130 W
 PLW13 0.09832609 W



F2 - Processing parameters
 SI 32768
 SF 100.7133280 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40

***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-(trifluoromethoxy)benzamide (3j)-1H NMR spectra**




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-(trifluoromethoxy)benzamide (**3j**)-¹⁹F spectra

AC-45-19F



N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-(trifluoromethoxy)benzamide (**3j**)-¹³C spectra

AC-45



```


Current Data Parameters
NAME          AC-45
EXPNO         2
PROCNO        1

F2 - Acquisition Parameters
Date_         20230206
Time          5.45 h
INSTRUM      AV4 400NB ANL-BLR-NMR-03
PROBHD       Z163739_0195 (
PULPROG      zgpg30
TD           65536
SOLVENT      CDCl3
NS           12000
DS           4
SWH          23809.523 Hz
FIDRES       0.726609 Hz
AQ           1.3762560 sec
RG           101
DW           21.000 usec
DE           6.50 usec
TE           298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TDO          1
SFO1         100.6228298 MHz
NUC1         13C
PC           2.67 usec
PI           8.00 usec
PLW1         99.25000000 W
SFO2         400.1316005 MHz
NUC2         1H
CPDPRG[2]    waltz65
PCPD2        90.00 usec
PLW2         24.03499985 W
PLW12        0.19059330 W
PLW13        0.09552535 W

F2 - Processing parameters
SI           32768
SF           100.6127472 MHz
WDW          EM
SSB          0
LB           2.00 Hz
GB           0
PC           1.40
    
```

3-cyano-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-fluorobenzamide (3I) -1 H NMR spectra

AK-792



Current Data Parameters
 NAME AK-792
 EXPNO 1
 PROCNO 1



F2 - Acquisition Parameters
 Date_ 20230113
 Time_ 17.26 h
 INSTRUM spect
 PROBHD Z116098_0561 ()
 PULPROG zg30
 TD 32768
 SOLVENT DMSO
 NS 16
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.489064 Hz
 AQ 2.0447233 sec
 RG 204.36
 DW 62.400 usec
 DE 6.50 usec
 TE 298.2 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.2324714 MHz
 NUC1 1H
 P0 3.33 usec
 P1 10.00 usec
 PLW1 16.45199966 W

F2 - Processing parameters
 SI 65536
 SF 400.2300024 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

3-cyano-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-fluorobenzamide (3I) -19F spectra


Batch NO-3L-19F

-102.994
-103.009
-103.021
-103.034
-103.049



3-cyano-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-fluorobenzamide (3I) -¹³C spectra

AK-792-13C




Current Data Parameters
 NAME AK-792
 EXPNO 12
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20230115
 Time 16.09 h
 INSTRUM Avance Neo Nanobay
 PROBHD Z163739_0079 ()
 PULPROG zgpg30
 TD 65536
 SOLVENT DMSO
 NS 12000
 DS 4
 SWH 23809.523 Hz
 FIDRES 0.726609 Hz
 AQ 1.3762560 sec
 RG 101
 DW 21.000 usec
 DE 6.50 usec
 TE 298.2 K
 D1 2.00000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.7234199 MHz
 NUC1 13C
 P0 3.33 usec
 P1 10.00 usec
 PLW1 59.21300125 W
 SFO2 400.5316021 MHz
 NUC2 1H
 CPDPRG[2] waltz65
 PCPD2 90.00 usec
 PLW2 15.97799969 W
 PLW12 0.19618130 W
 PLW13 0.09832609 W

F2 - Processing parameters
 SI 32768
 SF 100.7133983 MHz
 WDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3,5-difluorobenzamide (3m)- 1H NMR spectra

AK-D1-F





```

Current Data Parameters
NAME          AK-D1-F
EXPNO        10
PROCNO       1

F2 - Acquisition Parameters
Date_        20230202
Time         2.03 h
INSTRUM     AVNeo400-446284-Aragen
PROBHD      Z163739_0428 (
PULPROG     zg30
ID          32768
SOLVENT     CDCl3
NS          8
DS          2
SWH         8196.722 Hz
FIDRES      0.500288 Hz
AQ          1.9988480 sec
RG          101
DW          61.000 usec
DE          13.89 usec
TE          298.1 K
D1          1.00000000 sec
TD          1
SFO1        400.1424709 MHz
NUC1        1H
PQ          2.67 usec
P1          8.00 usec
PLW1        24.83499908 W



F2 - Processing parameters
SI          65536
SF          400.1400090 MHz
WDW         EM
SSB         0
LB          0.30 Hz
GB          0
PC          1.00
    
```

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3,5-difluorobenzamide (3m)- ¹⁹F spectra



N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3,5-difluorobenzamide (3m)- ¹³C spectra

AK-D1-F




```

Current Data Parameters
NAME          AK-D1-F
EXENO         66
PROCNO        1


F2 - Acquisition Parameters
Date_         20230205
Time          18.12 h
INSTRUM       AV4 400NB ANL-BLR-1
PROBHD        Z163739_0195 (
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            12000
DS            4
SWH           23809.523 Hz
FIDRES        0.726609 Hz
AQ            1.3762550 sec
RG            101
DW            21.000 usec
DE            6.50 usec
TE            298.2 K
D1            2.00000000 sec
D11           0.03000000 sec
TDO           1
SFO1          100.6228298 MHz
NUC1          13C
P0            2.67 usec
P1            8.00 usec
PLW1          99.25000000 W
SFO2          400.1316005 MHz
NUC2          1H
CPDPRG[Z]     wait=65
PCPD2         90.00 usec
PLW2          24.03499985 W
PLW12         0.19059330 W
PLW13         0.09552535 W

F2 - Processing parameters
SI            32758
SF            100.6127686 MHz
WDW           EM
SSB           0
LB            3.00 Hz
GB            0
PC            1.40
    
```

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-nitro benzamide (3o)-1H NMR spectra



AK-PNO2




```

Current Data Parameters
NAME          AK-PNO2
EXPNO         1
PROCNO        1


F2 - Acquisition Parameters
Date_         20230818
Time          17.16 h
INSTRUM       Avance Nec Nanobay
PROBHD        Z163739_0078 (
PULPROG       zg30
TD            32768
SOLVENT       DMSO-D6
NS            8
DS            2
SWH           8196.722 Hz
FIDRES        0.500288 Hz
AQ            1.9988480 sec
RG            38.1287
DW            61.000 usec
DE            13.54 usec
TE            298.2 K
D1            1.00000000 sec
TD0           1
SFO1          400.5324733 MHz
NUC1          1H
FO            3.33 usec
P1            10.00 usec
PLW1          14.34099960 W

F2 - Processing parameters
SI            65536
SF            400.5299715 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00
    
```


N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-nitro benzamide (3o)-13C spectra



AK-P-NO2





```

Current Data Parameters
NAME      AK-P-NO2A003
EXPNO    11
PROCNO   1

F2 - Acquisition Parameters
Date_    20230823
Time     8.02 h
INSTRUM  spect
PROBHD   Z116098_0561 (
PULPROG  zgpg30
TD       65536
SOLVENT  DMSO
NS       7000
DS       4
SWH      24038.461 Hz
FIDRES   0.733596 Hz
AQ       1.3631488 sec
RG       204.36
DW       20.800 usec
DE       6.50 usec
TE       300.9 K
D1       2.00000000 sec
D11      0.03000000 sec
TD0      1
SFO1     100.6479773 MHz
NUC1     13C
P0       3.33 usec
P1       10.00 usec
PLW1     71.33300018 W
SFO2     400.2316009 MHz
NUC2     1H
CPDPRG[2] waltz65
PCPD2    90.00 usec
PLW2     16.51199913 W
PLW12    0.20385000 W
PLW13    0.10253000 W

F2 - Processing parameters
SI       32768
SF       100.6379647 MHz
WDW      EM
SSB      0
LB       2.00 Hz
GB       0
PC       1.40
    
```

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-1 naphthamide (3p)- 1H NMR spectra





```

Current Data Parameters
NAME      AK-CRD
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20230909
Time     4.13 h
INSTRUM  AV4 400 Avajen Bangalore 505148
PROBHD   ZH55734_0h15 (
PULPROG  zgpg
TC       4.74K
SOLVENT  DMSO
NS       *
DS       *
SWH      8166.322 Hz
FIDRES   0.503268 Hz
AQ       1.9988460 sec
RG        101
DK       0.1000 usec
DE       3.89 usec
TE       289.1 K
D1       1.0000000 sec
TEC      1
SFO      403.162470 MHz
NUC1     13
P1       5.67 usec
PL1      0.00 usec
PL12     0.0000000 W

F2 - Processing parameters
SI       65535
SF       403.160315 MHz
WDW      EM
SSB      0
LB       0.30 Hz
GB       0
PC       1.00
    
```

N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-1 naphthamide (3p)-13C spectra




```

Current Data Parameters
NAME      AR-CRD
EXPNO    2
PROCNO   1


F2 - Acquisition Parameters
Date_    20230909
Time     11.41 h
INSTRUM  AV4 400 Aragon Bangalore 505143k
PROBHD   216.75mm QNP 1H 1
PULPROG  zgpg30
TE       300.2 K
SOLVENT  DMSO
NS       12800
DS       4
SWH      23409.525 Hz
FIDRES   0.724605 Hz
AQ       1.2762560 sec
RG       101
DW       21.000 usec
DE       6.50 usec
TE       298.1 K
D1       2.0000000 sec
D11      0.0000000 sec
TFC      1
SFO      100.6303141 MHz
NUC1     13C
NUC2     13C
PC1      0.67 usec
PC2      0.00 usec
PC3      99.54303225 W
SFO2     400.71515005 MHz
HUC2     0
CPHPRG1  waltz165
sFO2     91.00 usec
sLW2     21.898000000 MHz
PLW2     0.130000000 W
PLW3     0.050000000 W

F2 - Processing parameters
SI       32768
SF       100.6203120 MHz
RG       655
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
    
```


N,N'-(9,10-dioxo-9,10-dihydroanthracene-1,5-diyl)bis(pyrrolidine-2-carboxamide) -¹H NMR spectra




9,10-DIHYDROANTHRACENE PYRROLINE CARBOXAMIDE




N,N'-(9,10-dioxo-9,10-dihydroanthracene-1,5-diyl)bis(pyrrolidine-2-carboxamide) -¹³C spectra



9,10-DIHYDROANTHRACENE PYRROLINE CARBOXAMIDE-¹³C




tert-butyl 2-((2-ethylphenyl)carbamoyl)pyrrolidine-1-carboxylate (5a)



5a

T-BUTYLE-PYRROLIDINE-1-CARBOXYLATE




```

Current Data Parameters
NAME      T-BUTYLE-PYRROLIDINE-1-CARBOXYLATE
EXPNO     1
PROCNO    1


F2 - Acquisition Parameters
Date_     20210921
Time      11.47 h
INSTRUM   spect
PROBHD    z118098_0561_4
PULPROG   zg30
TD         32768
SOLVENT   DMSO
NS         32
DS         2
SWH        8012.820 Hz
FIDRES     0.489064 Hz
AQ         2.0447233 sec
RG         25.62
DW         62.400 usec
DE         6.50 usec
TE         299.0 K
D1         1.00000000 sec
TD0        1
SFO1      400.1324714 MHz
NUC1       1H
PC         3.33 usec
PI         10.00 usec
PLW1      16.51199913 W

F2 - Processing parameters
SI         65536
SF         400.1299961 MHz
WDW        EM
SSB        0
LB         0.80 Hz
GB         0
PC         1.00
    
```

tert-butyl 2-((2-ethylphenyl)carbamoyl)pyrrolidine-1-carboxylate (5a)



T-BUTYLE-PYRROLIDINE-1-CARBOXYLATE




```

Current Data Parameters
NAME: T-BUTYLE-PYRROLIDINE-1-CARBOXYLATE
EXPNO: 21
PROCNO: 1


F2 - Acquisition Parameters
Date_: 20230921
Time: 23.13 h
INSTRUM: spect
PROBHD: Z116098_0501_1
PULPROG: zgpg30
TD: 65536
SOLVENT: DMSO
NS: 1001
DS: 4
SFO: 24038.461 Hz
FIDRES: 0.733596 Hz
AQ: 1.2631488 sec
RG: 204.36
DW: 20.800 usec
DE: 6.50 usec
TE: 300.4 K
D1: 2.00000000 sec
D11: 0.00000000 sec
TD0: 1
SFO1: 100.6479773 MHz
NUC1: 13C
P0: 3.23 usec
P1: 10.00 usec
PLW1: 71.32300018 W
SFO2: 400.2316009 MHz
NUC2: 1H
CDEPRG[2]: waltz165
PCPD2: 90.00 usec
PLW2: 19.51196913 W
PLW12: 0.00000000 W
PLW13: 0.19251900 W

F2 - Processing parameters
SI: 32768
SF: 100.6479659 MHz
WDW: EM
SSB: 0
LB: 0.80 Hz
GB: 0
PC: 1.40
    
```

tert-butyl2-((2-(methoxycarbonyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (5c)



COMPOUND-10-DMSO




Current Data Parameters
 NAME COMPOUND-10-DMSO
 EXPNO 1
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20230922
 Time_ 12.08 h
 INSTRUM spect
 PROBHD z116098_0561 ()
 PULPROG zg30
 TD 32768
 SOLVENT DMSO
 NS 32
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.489064 Hz
 AQ 2.0447233 sec
 RG 149.06
 DW 62.400 usec
 DE 6.50 usec
 TE 300.2 K
 D1 1.00000000 sec
 TDO 1
 SFO1 400.2324714 MHz
 NUC1 1H
 P0 3.33 usec
 P1 10.00 usec
 PLW1 16.51199913 W

F2 - Processing parameters
 SI 65536
 SF 400.2300021 MHz
 WDW EM
 SSB 0
 LB 0.80 Hz
 GB 0
 PC 1.00

tert-butyl2-((2-(methoxycarbonyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (5c)



COMPOUND-10





```

Current Data Parameters
NAME          Compound-10
EXPNO         191
PROCNO        1

F2 - Acquisition Parameters
Date_         20230923
Time          0.51 h
INSTRUM      spect
PROBHD       Z116098_0561 (
PULPROG      zgpg30
TD           65536
SOLVENT      DMSO
NS           3072
DS           4
SWH          24038.461 Hz
FIDRES       0.733596 Hz
AQ           1.3631488 sec
RG           204.36
DW           20.800 usec
DE           6.50 usec
TE           300.5 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0          1
SFO1         100.6479773 MHz
NUC1         13C
FO           3.33 usec
P1           10.00 usec
PLW1         71.33300018 W
SFO2         400.2316009 MHz
NUC2         1H
CPDPRG[2]   waltz165
PCPD2        90.00 usec
PLW2         16.51199913 W
PLW12        0.20385000 W
PLW13        0.10253000 W

F2 - Processing parameters
SI           32768
SF           100.6379654 MHz
WDW          EM
SSB          0
LB           2.00 Hz
GB           0
PC           1.40
    
```

tert-butyl 2-((6-methoxypyridazin-3-yl)carbamoyl)pyrrolidine-1-carboxylate (5d)




Current Data Parameters
 NAME COMPOUND-12-DMSO
 EXPNO 1
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20230925
 Time 11.34 h
 INSTRUM spect
 PROBHD Z116098_0561 ()
 PULPROG zg30
 TD 32768
 SOLVENT DMSO
 NS 64
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.489064 Hz
 AQ 2.0447233 sec
 RG 204.36
 DW 62.400 usec
 DE 6.50 usec
 TE 298.9 K
 D1 1.00000000 sec
 TD0 1
 SFO1 400.2324714 MHz
 NUC1 1H
 P0 3.33 usec
 P1 10.00 usec
 PLW1 16.51199913 W

F2 - Processing parameters
 SI 65536
 SF 400.2300025 MHz
 WDW EM
 SSB 0
 LB 0.80 Hz
 GB 0
 PC 1.00

tert-butyl 2-((3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate



WITHOUT-BROMO COMPOUND-CDCL3




```

Current Data Parameters
NAME      WITHOUT-BROMO COMPOUND-CDCL3
EXPNO     1
PROCNO    1


F2 - Acquisition Parameters
Date_     20230927
Time      12.42 h
INSTRUM   spect
PROBRG    Z116098_0561.f
PULPROG   zg30
TD         32768
SOLVENT   CDCL3
NS         64
DS         2
SWH        8012.820 Hz
FIDRES     0.489064 Hz
AQ         2.0447233 sec
RG         28.21
DM         62.400 usec
DE         6.50 usec
TE         299.4 K
D1         1.00000000 sec
TDO        1
SFO1       400.2324714 MHz
NUC1       1H
PC         3.33 usec
P1         10.00 usec
PLWL       16.51199913 W

F2 - Processing parameters
SI         65536
SF         400.2299998 MHz
WDW        EM
SSB        0
LB         0.80 Hz
GB         0
PC         1.00
    
```

tert-butyl 2-((3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate



WITHAOUT BROMO COMPOUND




```

Current Data Parameters
NAME      WITHAOUT BROMO COMPOUND
EXPNO    22
PROCNO   1


F2 - Acquisition Parameters
Date_    20230929
Time     23.21 h
INSTRUM  spect
PROBHD   Z116098_0561 (
PULPROG  zgpg30
TD       65536
SOLVENT  cdcl3
NS       4000
DS       4
SWH      24038.461 Hz
FIDRES   0.733596 Hz
AQ       1.3631488 sec
RG       204.36
DW       20.800 usec
DE       6.50 usec
TE       298.1 K
D1       2.00000000 sec
D11      0.03000000 sec
TDO      1
SFO1     100.6479773 MHz
NUC1     13C
P0       3.33 usec
P1       10.00 usec
PLW1     71.33300018 W
SFO2     400.2316009 MHz
NUC2     1H
CPDPRG2  waltz65
PCPD2    90.00 usec
PLW2     16.51199913 W
PLW12    0.20385000 W
PLW13    0.10253000 W

F2 - Processing parameters
SI       32768
SF       100.6379135 MHz
WDW      EM
SSB      0
LB       0.80 Hz
GB       0
PC       1.40
  
```

tert-butyl 2-((5-bromo-3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate



WITH-BROMO COMPOUND-CDCL3



```


Current Data Parameters
NAME      WITH-BROMO COMPOUND-CDCL3
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20230927
Time     12.36 h
INSTRUM  spect
PROBHD   Z116098_0561 (
PULPROG  zg30
TD        32768
SOLVENT  CDCL3
NS        64
DS        2
SWH       8012.820 Hz
FIDRES    0.489064 Hz
AQ        2.0447233 sec
RG        19.8
DW        62.400 usec
DE        6.50 usec
TE        299.4 K
D1        1.00000000 sec
TD0       1
SFO1     400.2324714 MHz
NUC1      1H
PQ        3.33 usec
P1        10.00 usec
PLW1     16.51199913 W


F2 - Processing parameters
SI        65536
SF        400.2299913 MHz
WDW       EM
SSB       0
LB        0.80 Hz
GB        0
PC        1.00

```

tert-butyl 2-((5-bromo-3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate



Bromo COMPUND-CDCL3



```


Current Data Parameters
NAME      Bromo COMPUND-CDCL3
EXPNO    2
PROCNO   1

F2 - Acquisition Parameters
Date_    20230929
Time     23.20 h
INSTRUM  AV4 400NB ANL-BLR-NMR-03
PROBHD   Z163739_0195 (
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       4000
DS       4
SWH      23809.523 Hz
FIDRES   0.726609 Hz
AQ       1.3762560 sec
RG        191
DW       21.000 usec
DE       6.50 usec
TE       298.1 K
D1       2.00000000 sec
D11      0.03000000 sec
TD0      1
SFO1     100.6228298 MHz
NUC1     13C
P0       2.67 usec
P1       8.00 usec
PLW1     99.25000000 W
SFO2     400.1316005 MHz
NUC2     1H
CPDPRG[2] waltz65
PCPD2    90.00 usec
PLW2     24.03499985 W
PLW12    0.19059330 W
PLW13    0.09552535 W


F2 - Processing parameters
SI       32768
SF       100.6127685 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
  
```

7. HRMS DATA


(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide




D-PROLINE-DERMATME #201 RT: 1.97 AV: 1 NL: 1.98E8
T: FTMS - c ESI Full ms [100.0000-1500.0000]



(S) -N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)pyrrolidine-2-carboxamide





L-PROLINE-DERIVATIVE #201 RT: 1.97 AV: 1 NL: 4.73E9
T: FTMS +c ESI Full ms [100.0000-1500.0000]





(R)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide

AK PIP 2 #16-39 RT: 0.12-0.30 AV: 24 NL: 1.59E7
T: FTMS - p ESI Full ms [200.0000-2000.0000]
335.1353




(S)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)piperidine-2-carboxamide


AK PIP 1 #151-206 RT: 1.16-1.58 AV: 56 NL: 2.75E7
T: FTMS + p ESI Full ms [200.0000-2000.0000]
335.1352




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-((1s,4s)-4-methylcyclohexyl)acetamide (3c)




Sample-3 #26-32 RT: 0.25-0.29 AV: 3 NL: 9.91E6
T: FTMS - c ESI Full ms [100.0000-500.0000]




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-5-((3*a*S,4*S*,6*a*R)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamide (3d)




AK-BIOTIN #486-500 RT: 4.75-4.87 AV: 7 NL: 2.99E8
T: FTMS + c ESI Full ms [150.0000-900.0000]





4,4-difluorocyclohexyl)-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide (3e)-





Sample-2 #126 RT: 1.09 AV: 1 NL: 1.76E6
T: FTMS - c ESI s/d-20.00 Full ms [200.0000-2000.0000]




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-hydroxybutanamide(3f)




***N*-(9, 10-dioxo-9,10-dihydroanthracen-1-yl)-3-methylbenzamide (3h)**





***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-methoxybenzamide (3i)**




AK-500 #627-640 RT: 6.13-6.25 AV: 7 NL: 7.31E7
T: FTMS + c ESI Full ms [150.0000-800.0000]




***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-(trifluoromethoxy)benzamide (3j)**




***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3,5-dimethylbenzamide (3k)**




AC-37 #697-705 RT: 6.79-6.87 AV: 5 NL: 2.54E8
T: FTMS + c ESI Full ms [150.0000-800.0000]




3-cyano-N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-4-fluorobenzamide (3I)




AK-792 #611-618 RT: 5.97-6.03 AV: 4 NL: 1.45E8
T: FTMS + c ESI Full ms [150.0000-800.0000]





***N*-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-3,5-difluorobenzamide (3m)**




AK-DIF #656-661 RT: 6.42-6.46 AV: 3 NL: 1.78E8
T: FTMS + c ESI Full ms [150.0000-800.0000]




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-2-nitrobenzamide (3o)




N-(9,10-dioxo-9,10-dihydroanthracen-1-yl)-1 naphthamide (3p)




AK-CRD-378 #202 RT: 3.75 AV: 1 NL: 1.50E2
F: ITMS - c ESI Full ms [110.00-2000.00]




AK-CRD-378 #203 RT: 3.79 AV: 1 NL: 3.16E3
F: ITMS + c ESI Full ms [110.00-2000.00]




N,N'-(9,10-dioxo-9,10-dihydroanthracene-1,5-diyl)bis(pyrrolidine-2-carboxamide) (6)



Diamine #19 RT: 0.14 AV: 1 NL: 9.42E8
T: FTMS + p ESI Full ms [100 0000-1500 0000]




tert-butyl 2-((2-ethylphenyl)carbamoyl)pyrrolidine-1-carboxylate




Sample ID : t_butyl_pyrrolidine_1_Carboxylate
Date : 21-09-2023


Instrument ID: ANL-BLR-LCMS-020




tert-butyl 2-((2-(methoxycarbonyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate




Compound_10 #29 RT: 0.21 AV: 1 NL: 5.92E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]




tert-butyl 2-((6-methoxypyridazin-3-yl)carbamoyl)pyrrolidine-1-carboxylate




Compound_12_1 #27 RT: 0.20 AV: 1 NL: 4.38E8
T: FTMS + p ESI Full ms [100.0000-1500.0000]





tert-butyl 2-((3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate



Compound_without_Bromine2 #31 RT: 0.23 AV: 1 NL: 9.03E8
T: FTMS + p ESIFull.ms [100.0000-1500.0000]





tert-butyl 2-((5-bromo-3-(methoxycarbonyl)-2-methylphenyl)carbamoyl)pyrrolidine-1-carboxylate





8. Super critical Fluid chromatography Data

Optimisation of condition for SFC separation of compounds (+)-3a' + (-)-3a





SFC screening chromatogram of D and L-proline ((±)-3a) amide derivatives in different chiral columns.

Optimisation of condition for SFC separation of compounds (+)-**3b'** and (+)-**3b**



SFC screening chromatogram of D and L-Piperidine (\pm)-**3b**) amide derivatives in different chiral columns.

Optimisation of condition for SFC separation of compounds **3c'** and **3c''**




Successful separation of compound **1** and *cis* **3c'** and *trans* **3c''** isomers using Chiralpak IA column with Methanol as Co-solvent.

Chiral purity SFC method for 4a & 4a'

SampleName: DL-Proline	Date Acquired 25-Jul-2019 12:08:40 PM IST
Vial : 1:B,1	System Name: ANL_BLR_UPC2_01
Injection Volume : 8.00 uL	Method Set: 3g_30_1500PSI_B2_C1_C6
Column Name: Chiralpak IG-3(4.6X150)mm;3u	Processed Channel Descr: PDA Spectrum PDA 262.0 nm (PDA Spectrum (210-400)nm)
File Name: DL-Proline	

Analytical SFC Conditions :	
Column/dimensions	:Chiralpak IG-3(4.6X150)mm;3u
% CO2	:70%
% Co solvent	:30%(0.2% 7M Methanolic Ammonia in Acetonitrile:Methanol)(1:1)
Total Flow	:3.00 g/min
Back Pressure	:1500PSI
Temperature (degree)	:30




Peak Results

	RT	Area	% Area
1	3.393	5476142	50.03
2	4.436	5489549	49.97

Chiral purity SFC method for 4a1

Sample Name: D-Proline	Date Acquired 25-Jul-2019 01:04:17 PM IST
Vial : 1:B,6	System Name: ANL_BLR_UPC2_01
Injection Volume : 8.00 uL	Method Set: 3g_30_1500PSI_B2_C1_C6
Column Name: Chiralpak IG-3(4.6X150)mm;3u	Processed Channel Descr: PDA Spectrum PDA 262.0 nm (PDA Spectrum (210-400)nm)
File Name : D-Proline	

Analytical SFC Conditions :	
Column/dimensions	:Chiralpak IG-3(4.6X150)mm;3u
% CO ₂	:70%
% Co solvent	:30%(0.2% 7M Methanolic Ammonia in Acetonitrile:Methanol)(1:1)
Total Flow	:3.00 g/min
Back Pressure	:1500PSI
Temperature (de gree)	:30




Peak Results

	RT	Area	% Area
1	3.353	12823747	99.20
2	4.616	103470	0.80

Chiral purity SFC method for 4a

SampleName: L-Proline	Date Acquired 25-Jul-2019 12:19:56 PM IST
Vial : 1:B,2	System Name: ANL_BLR_UPC2_01
Injection Volume : 8.00 uL	Method Set: 3g_30_1500PSI_B2_C1_C6
Column Name: Chiralpak IG-3(4.6X150)mm;3u	Processed Channel Descr: PDA Spectrum PDA 262.0 nm (PDA Spectrum (210-400)nm)
File Name: L-Proline	

Analytical SFC Conditions :	
Column/dimensions	:Chiralpak IG-3(4.6X150)mm;3u
% CO2	:70%
% Co solvent	:30%(0.2% 7M Methanolic Ammonia in Acetonitrile:Methanol)(1:1)
Total Flow	:3.00 g/min
Back Pressure	:1500PSI
Temperature (degree)	:30




Peak Results

	RT	Area	% Area
1	3.384	26501	0.64
2	4.418	4093742	99.36

Chiral purity SFC method for 4b & 4b'

SampleName: pipecolic acid derivative	Date Acquired 13-Aug-2019 05:08:43 PM IST
Vial : 2:C,3	System Name: ANL_BLR_UPC2_01
Injection Volume : 10.00 uL	Method Set: 3g_30_1500PSI_B1_C1_C4
Column Name: Chiralpak IA-3(4.6X150)mm;3u	Processed Channel Descr: PDA Spectrum PDA 262.0 nm (PDA Spectrum (210-400)nm)
File Name :	

Analytical SFC Conditions	
Column/dimensions	:Chiralpak IA-3(4.6X150)mm;3u
% CO2	:70%
% Co solvent	:30% of (MEOH)
Total Flow	:3.00 g/min
Back Pressure	:1500PSI
Temperature (degree)	:30




Peak Results

RT	Area	% Area
1 2.591	3070367	49.68
2 3.785	3109648	50.32

Chiral purity SFC method for 4b'

SampleName: pipecolic acid derivative-PK-2	Date Acquired 14-Aug-2019 12:30:55 PM IST
Vial : 2:D,6	System Name: ANL_BLR_UPC2_01
Injection Volume : 10.00 uL	Method Set: 3g_30_1500PSI_B1_C1_C4
Column Name: Chiralpak IA-3(4.6X150)mm;3u	Processed Channel Descr: PDA Spectrum PDA 262.0 nm (PDA Spectrum (210-400nm))
File Name: pipecolic acid derivative-PK-2	

Analytical SFC Conditions	
Column/dimensions	:Chiralpak IA(4.6X150)mm;3u
% CO2	:70%
% Co solvent	:30%(Methanol)
Total Flow	:3.00 g/min
Back Pressure	:1500PSI
Temperature (degree)	:30




Peak Results

	RT	Area	% Area
1	2.613	1566	0.07
2	3.799	2301688	99.93

Chiral purity SFC method for 4b

SampleName: pipecolic acid derivative-PK-1	Date Acquired 14-Aug-2019 12:12:23 PM IST
Vial : 2:D,5	System Name: ANL_BLR_UPC2_01
Injection Volume : 10.00 uL	Method Set: 3g_30_1500PSI_B1_C1_C4
Column Name: Chiralpak IA-3(4.6X150)mm;3u	Processed Channel Descr: PDA Spectrum PDA 262.0 nm (PDA Spectrum (210-400)nm)
File Name: pipecolic acid derivative-PK-1	

Analytical SFC Conditions	
Column/dimensions	:Chiralpak IA(4.6X150)mm;3u
% CO2	:70%
% Co solvent	:30%(Methanol)
Total Flow	:3.00 g/min
Back Pressure	:1500PSI
Temperature (degree)	:30



Peak Results

RT	Area	% Area
1 2.630	5771310	99.99
2 3.865	941	0.01

9. Optical Rotation values for compounds 4a, 4a' 4b and 4b'

D-Proline derivative


[Data Information]
Creation Date 05-Sep-2019 16:21

[Measurement Information]
Instrument Name Polarimeter
Model Name P-2000
Serial No. A112361232
Polarizer Dichrom
Faraday Cell Flint Glass

Accessory PTC-262
Accessory S/N B024761481
Temperature 25.00 C
Control Sensor Holder
Monitor Sensor Holder
Start Mode Start immediately

Light Source WI
Monitor wavelength 589 nm
D.I.T. 5 sec
No. of cycle 5
Cycle interval 5 sec
Temp. Monitor Holder
Temp. Corr. Factor 0 at 25 C
Aperture(S) 3.0mm
Aperture(L) Auto
Mode Specific O.R.
Path Length 100 mm
Concentration 0.1 w/v%
Water content of sample 0 %
Factor 1

[Comment]
Sample name D-Proline derivative
Comment 0.1% in Acetonitrile
User Administrator
Workgroup QC
Division QC
Company GVK



	No.	Sample No.	Mode	Calc. Data	Meas. Data	PMT Voltage[V]	Temperature(C)	Blank	Comment	
1	*	1	D-Proline derivative-1	Specific O.R.	+36.2800	+0.0363	352	25.00	+0.0051	0.1% in Acetonitrile
2	*	2	D-Proline derivative-2	Specific O.R.	+36.4800	+0.0365	383	24.99	+0.0051	0.1% in Acetonitrile
3	*	3	D-Proline derivative-3	Specific O.R.	+35.7800	+0.0358	362	24.99	+0.0051	0.1% in Acetonitrile
4	*	4	D-Proline derivative-4	Specific O.R.	+36.4800	+0.0365	382	24.99	+0.0051	0.1% in Acetonitrile
5	*	5	D-Proline derivative-5	Specific O.R.	+35.9800	+0.0360	386	24.99	+0.0051	0.1% in Acetonitrile
6	*	6		Avg.	+36.2000					
7		7		S.D	0.3114					
8		8		C.V	0.8604					

L-Proline derivative


[Data Information]
Creation Date 05-Sep-2019 12:36

[Measurement Information]
Instrument Name Polarimeter
Model Name P-2000
Serial No. A112361232
Polarizer Dichrom
Faraday Cell Flint Glass


Accessory PTC-262
Accessory S/N B024761481
Temperature 25.00 C
Control Sensor Holder
Monitor Sensor Holder
Start Mode Start immediately

Light Source WI
Monitor wavelength 589 nm
D.I.T. 5 sec
No. of cycle 5
Cycle interval 5 sec
Temp. Monitor Holder
Temp. Corr. Factor 0 at 25 C
Aperture(S) 3.0mm
Aperture(L) Auto
Mode Specific O.R.
Path Length 100 mm
Concentration 0.1 w/v%
Water content of sample 0 %
Factor 1

[Comment]
Sample name L-Proline derivative
Comment 0.1% in Acetonitrile
User Administrator
Workgroup QC
Division QC
Company GVK



	No.	Sample No.	Mode	Calc. Data	Meas. Data	PMT Voltage[V]	Temperature(C)	Blank	Comment	
1	*	1	L-Proline derivative-1	Specific O.R.	-44.2200	-0.0442	422	25.01	+0.0051	0.1% in Acetonitrile
2	*	2	L-Proline derivative-2	Specific O.R.	-40.1200	-0.0401	427	25.01	+0.0051	0.1% in Acetonitrile
3	*	3	L-Proline derivative-3	Specific O.R.	-42.0200	-0.0420	430	25.00	+0.0051	0.1% in Acetonitrile
4	*	4	L-Proline derivative-4	Specific O.R.	-41.3200	-0.0413	412	25.00	+0.0051	0.1% in Acetonitrile
5	*	5	L-Proline derivative-5	Specific O.R.	-40.9200	-0.0409	285	24.99	+0.0051	0.1% in Acetonitrile
6	*	6		Avg.	-41.7200					
7		7		S.D	1.5572					
8		8		C.V	3.7326					



D-pipecolic acid derivative

[Data Information]

Creation Date 05-Sep-2019 14:49

[Measurement Information]

Instrument Name Polarimeter
 Model Name P-2000
 Serial No. A112361232
 Polarizer Dichrom
 Faraday Cell Flint Glass

Accessory PTC-262
 Accessory S/N B024761481
 Temperature 25.00 C
 Control Sensor Holder
 Monitor Sensor Holder
 Start Mode Start immediately


Light Source W1
 Monitor wavelength 589 nm
 D.I.T. 5 sec
 No. of cycle 5
 Cycle interval 5 sec
 Temp. Monitor Holder
 Temp. Corr. Factor 0 at 25 C
 Aperture(S) 3.0mm
 Aperture(L) Auto
 Mode Specific O.R.
 Path Length 100 mm
 Concentration 0.1 w/v%

Water content of sample 0 %
 Factor 1

[Comment]

Sample name D-pipecolic acid derivative
 Comment 0.1% in Acetonitrile
 User Administrator
 Workgroup QC
 Division QC
 Company GVK

	No.	Sample No.	Mode	Calc. Data	Meas. Data	PMT Voltage[V]	Temperature(C)	Blank	Comment
1	*	1	D-pipecolic acid derivative-1	Specific O.R.	+26.8800	+0.0269	411	24.99	+0.0051 0.1% in Acetonitrile
2	*	2	D-pipecolic acid derivative-2	Specific O.R.	+26.2800	+0.0263	410	24.99	+0.0051 0.1% in Acetonitrile
3	*	3	D-pipecolic acid derivative-3	Specific O.R.	+26.8800	+0.0269	328	24.99	+0.0051 0.1% in Acetonitrile
4	*	4	D-pipecolic acid derivative-4	Specific O.R.	+25.4800	+0.0255	370	25.00	+0.0051 0.1% in Acetonitrile
5	*	5	D-pipecolic acid derivative-5	Specific O.R.	+28.3800	+0.0284	403	25.00	+0.0051 0.1% in Acetonitrile
6	*	6	Avg.		+26.7800				
7		7	S.D		1.0630				
8		8	C.V		3.9694				



L-pipecolic acid derivative

[Data Information]
 Creation Date 05-Sep-2019 15:18

[Measurement Information]
 Instrument Name Polarimeter
 Model Name P-2000
 Serial No. A112361232
 Polarizer Dichrom
 Faraday Cell Flint Glass

Accessory PTC-262
 Accessory S/N B024761481
 Temperature 25.00 C
 Control Sensor Holder
 Monitor Sensor Holder
 Start Mode Start immediately

Light Source WI
 Monitor wavelength 589 nm
 D.I.T. 5 sec
 No. of cycle 5
 Cycle interval 5 sec
 Temp. Monitor Holder
 Temp. Corr. Factor 0 at 25 C
 Aperture(S) 3.0mm
 Aperture(L) Auto
 Mode Specific O.R.
 Path Length 100 mm
 Concentration 0.1 w/v%
 Water content of sample 0 %
 Factor 1

[Comment]
 Sample name L-pipecolic acid derivative
 Comment 0.1% in Acetonitrile
 User Administrator
 Workgroup QC
 Division QC
 Company GVK

	No.	Sample No.	Mode	Calc. Data	Meas. Data	PMT Voltage[V]	Temperature(C)	Blank	Comment
1	*	1	L-pipecolic acid derivative-1	Specific O.R.	-26.1200	-0.0261	397	25.01	+0.0051 0.1% in Acetonitrile
2	*	2	L-pipecolic acid derivative-2	Specific O.R.	-26.6200	-0.0266	355	25.01	+0.0051 0.1% in Acetonitrile
3	*	3	L-pipecolic acid derivative-3	Specific O.R.	-27.9200	-0.0279	296	25.00	+0.0051 0.1% in Acetonitrile
4	*	4	L-pipecolic acid derivative-4	Specific O.R.	-26.8200	-0.0268	367	25.00	+0.0051 0.1% in Acetonitrile
5	*	5	L-pipecolic acid derivative-5	Specific O.R.	-27.6200	-0.0276	411	24.99	+0.0051 0.1% in Acetonitrile
6	*	6	Avg.		-27.0200				
7		7	S.D		0.7382				
8		8	C.V		2.7322				

